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INTRODUCTION 
Thesis Organization 
My work involves characterizing the properties of FREBP (basic Fibroblast Growth 
Factor Response Element Binding Protein) and identifying the signal transduction pathways 
that are involved in its regulation. In the introduction I have first outlined the role of 
extracellular matrix (ECM) in various tissue remodeling events. Then I have discussed about 
the ECM receptors, like integrins, and the various pathways that may be involved in the 
regulation of the FREBP. I have limited the scope of my discussion of specific molecules to 
their involvement in the signal transduction pathways relating to the ECM. A brief discussion 
follows this section that describes the ECM enzymes along with the important roles that they 
play in tissue remodeling events and cancer. The next section offers a brief introduction to 
mitogen regulated protein3 (MRP3), a bFGF regulated gene containing the basic-fibroblast 
growth factor response element (FRE) in its proximal promoter, regulation of gene 
expression by Fibroblast growth factor's (FGF's) and the AP-1 transcriptional element. 
MRP3 is a member of the MRP/PLF family of glycoproteins. Subsequently the dissertation 
consists of background information on FRE, the transcriptional element that binds to our 
transcription factor FRE-binding protein (FREBP). A brief summary of the work done on 
the FREBP to date follows. Currently purification of FREBP is underway in our lab with the 
results looking very promising. Finally the document describes in relative detail the 
experimental methods, results and a brief discussion of the study done in order to 
characterize this transcription factor in the laboratory. 
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ECM and tissue remodeling 
Our understanding of the importance of the extracellular matrix (ECM) has grown over 
the past 15 years from it being viewed as primarily a structural support mechanism for the 
cell to now being demonstrated to play a maj or role in other processes like growth factor 
regulation. The ECM has also been shown to modulate growth factor binding proteins and 
the initiation of signal transduction pathways that control gene expression by interacting with 
cell surface receptors. The combined activities of the molecules within the cell and the 
molecules in the ECM have a major effect on the behavior and functioning of the cell. The 
different ECM components like collagens, fibronectin, fibrinogen, laminin and plasminogen 
interact with the various cell surface receptors within the cell like integrins, cadherins, Axl, 
ephrins, immunoglobulins and selectins. These interactions could lead to upregulation or 
downregulation of various signal transduction pathways like the MAP kinase pathway, PI-3 
kinase pathway and FAK pathway resulting in different outcomes from apoptosis to cell 
differentiation [ 1 ] . ECM remodeling is an integral part of many physiological phenomenon 
like wound healing, differentiation during development, neovascularisation, mammary gland 
and uterine changes during the menstrual cycle and trophoblastic changes during pregnancy. 
Some pathological conditions where the ECM plays a maj or role are inflammation, 
degradation of bone and joints, autoimmune diseases and cellular proliferation in cancer. 
Clinical and basic research on the development of cancer, its metastatic behavior and the 
subsequent activation of the metastatic cascade at other places have established that there is 
an active involvement of the ECM and its various adhesion molecules in cancer [2] . Due to 
their varied impact on numerous cellular functions and their ability to influence the 
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intracellular milieu, it is extremely important to define methods to control the functioning of 
ECM proteins within the cellular environment. 
ECM receptors: integrins 
Some of the cell surface receptors that interact with the ECM are the integrins, cadherins, 
Axl, ephrins, immunoglobulins, selectins and the Notch family of proteins [3]. The main 
receptors that are associated with the ECM are from the integrin family, which are 
transmembrane glycoproteins that influence intrinsic and extrinsic events of cellular behavior 
[4]. All integrin receptors consist of heterodimers. The alpha and beta subunits consist of an 
amino-terminal extracellular domain, a transmembrane domain and a short cytoplasmic 
domain. These subunits can associate in multiple combinations [5]. Interestingly, these 
receptors can act in both directions and are able to transmit signals from the inside to outside 
of the cell and vice versa [6] [7]. Integrins are expressed under different physiological 
conditions but this expression varies considerably with different cell types [8]. 
A variety of proteins are identified as integrin ligands namely the collagens, fibronectin, 
fibrinogen, laminin and plasminogen [9] . Each subunit of integrin receptors can bind to 
different ligands. These ligands have been categorized on the basis of their binding 
specificity with respect to different integrin receptor subunits and their respective functions. 
Beta subunit cytoplasmic domain binding ligands include the actin-binding proteins like 
talin, filamin and myosin; signaling proteins like FAK and ILK; as well as other adaptor 
proteins like Grb2, paxillin, Shc and caveolin-1. A second group of ligands binding to the 
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alpha subunit cytoplasmic domain consist of calreticulin, caveolin-1 and F-actin [10]. 
Previously, certain cell surface receptor types were believed to respond exclusively to 
particular ligands. For example tyrosine kinase receptors respond to growth factors. Now 
there is evidence that ECM molecules, like collagens, are also ligands for certain tyrosine 
kinase receptors [11]. There also exists considerable evidence of interaction and cross-talk 
between growth factor and ECM regulated pathways. 
There are a variety of cell responses that ECM receptors regulate including cell 
spreading, proliferation, migration, differentiation and progression through the G1 phase of 
the cell cycle [ 12], wound repair, angiogenesis, the inflammatory response, apoptosis, and 
gene expression [13]. Interaction of integrins with the ECM is known to have an effect on 
their half lives and the adhesion-dependent signals that they transmit [14]. Integrins associate 
with their ECM ligands and some other adaptor proteins, bringing about a change in the actin 
cytoskeleton to produce large protein complexes called focal adhesions, so named because 
they form and accumulate as a result of cell adhesion. These focal adhesion complexes are 
aggregations of many proteins that have signaling initiation properties [15]. Formation of 
these focal adhesion complexes initiates phosphorylation of tyrosine residues on certain 
signal transduction molecules like Src kinase, phosphatidyl inositol-3 Kinase (PI3K), focal 
adhesion kinase (FAK) [16] as well as ERK1/2 and MEK from the MAP kinase pathway 
[17]. Recent studies have shown that the cell can also regulate focal adhesion assembly 
following integrin mediated cell adhesion [18]. In the later part of my discussion, I will 
elaborate in detail the mechanism and various methods involved in the activation of these 
molecules and also the different pathways in which they participate. 
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The integrins closely interact with the ECM to play a significant role in tissue remodeling 
processes like wound healing and development [19]. During these processes integrins not 
only facilitate attachment of the cells to the matrix but, under stressful conditions, they 
compensate for the negative effects of low level of growth factors. This interaction plays a 
very important role in defining the behavior of normal cells and provides valuable 
discriminatory criteria between the normal cells and the cancerous/neoplastic cells [20]. The 
ability of integrins to act in this way is mostly attributed to their ability to activate upstream 
molecular pathways via activation of nuclear receptors and second messenger systems that 
initiate downstream signaling mechanisms, which influence transcription, gene expression 
and protein synthesis [21]. These cascades establish links between the cell's outer 
environment and its inner milieu [22]. Furthermore it is evident that among all adhesion 
molecules the role of certain integrins has been specifically identified in cell spreading, 
proliferation, migration, differentiation [12] as well as oncogenesis [23], whereas the 
expression of integrins in cell lines and tumor tissues correlates directly with the 
development of cancerous pathology [24]. For example, in Chinese hamster ovary cells there 
is an inverse relation of the expression of integrin proteins like (3 and a5/ail [25] and the 
development of the tumorigenic phenotype [26]. Studies have also shown an association 
between lower expression of other integrins like ,61, aV(33 and x6(31 and cancerous 
pathologies of ovarian carcinoma [27] and colorectal cancer [28]. Osteosarcoma cell lines 
over expressing a5/,61 showed increased cell adhesion to type I collagen and increased cell 
migration and invasion rate compared to the wild type cells [29]. In two-dimensional cell 
migration assays using mouse mammary carcinoma cells, antibodies against al, a2, a6 and 
X31 decreased cell invasion on a reconstituted basement membrane, against a6 and ,61 
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decreased cell locomotion and against (31 interfered with cell adhesion to basement 
membrane [30]. There have also been studies showing a direct effect of extracellular matrix 
attachment on gene expression. For example, cultured primary mammary epithelial cells 
show an increase in expression of the genes encoding alpha-casein, beta casein, gamma- 
casein and transferrin in response to ECM attachment [31] [32]. Together these data indicate 
that it is of utmost importance to outline the different pathways that are stimulated under 
these conditions especially focusing on identifying key players that could be used as a site of 
inhibition for cell processes like movement, proliferation and angiogenesis during cancer 
treatment and could aid in a better therapeutic control of numerous cancer forms and their 
metastasis. 
The hallmark of cancerous cells in-vivo is their ability to survive and proliferate and 
move to different sites within the body mainly by overcoming the need of integrin mediated 
adhesion or anchorage dependence [33]. These intercellular and cell to ECM attachments and 
their combined interactions are well known to play a very important role in making cells 
invasive and malignant [34]. The role of integrins and the various signal transduction 
pathways activated by them like the PI-3 kinase pathway, play a role in the regulation of 
cellular functions like tumor development and progression. The integrins through their 
interaction with the cytoskeletal components like laminin and type I collagen can initiate 
signals via tyrosine kinases that effect several other growth regulatory cascades. The 
activation of the Rho-family of small GTPases acts on members of the MAP kinase pathway 
like Ras and regulate cell signals like cell growth, motility, survival and invasiveness [35- 
37]. More deaths are caused by the secondary metastasis of a particular type of cancer rather 
than the primary itself and generally by the time the primary tumor is detected it is too late 
for any curative measures. Cancer metastasis is facilitated by a joint effort between cell 
adhesion by integrins and matrix degradation by different proteases [38]. This important 
phenomenon of metastasis is of most concern in cancer and now, with more recent and 
detailed data, integrins have been established as playing a important role in metastasis [39]. 
ECM regulated pathways 
Integrins are vital in the different growth factor signaling pathways [40]. Integrins are 
known to affect biological processes similar to those affected by growth factors like cell 
migration and programmed cell death. [41]. Oncogenic transformation of cell lines like ratl, 
NRK and NIL8 by Rous sarcoma virus or murine sarcoma virus leads to lower expression of 
the a5~i1 integrins and reduced ability to establish fibronectin assembly. These transformed 
cells demonstrate remarkable preponderance to the development of cancerous changes 
indicating a close co-relation between the protein expression and disease development [42]. 
There is extensive cross talk between integrin and growth factor receptors that is 
accomplished either by their clustering together on the cell membrane or by interaction of 
proteins or signals at different points downstream in the signal transduction pathways 
initiated by these receptors [43]. This cross-talk is further established when the same signal 
transduction pathways are initiated by both integrins and growth factors like the MAP kinase, 
PI-3 kinase and Focal adhesion kinase [44] [45]. The discussion that follows elaborates on 
these pathways in more detail. 
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The main pathways that will be discussed herein are the mitogen activated protein kinase 
(MAPK), focal adhesion kinase (FAK) and phosphatidyl inositol-3 kinase (PI-3 K) pathway 
[46] . All these pathways are activated as part of the cellular processes and biological 
phenomenon that I am studying and some of their molecules are known to be very important 
players in these processes. From research already done we know that there are common 
molecules like Src kinase, PI-3 kinase, MEK, FAK, Ras and Rho family of GTPases that 
participate in several of these pathways and regulate various cell functions like growth, 
spreading, migration, survival, proliferation, apoptosis and invasiveness [47] . Most of these 
molecules are associated with, and activated in, different cancers and some of them are also 
being used clinically as inhibitors along with other therapeutic inhibitors. 
The mitogen-activated kinases are cytosolic serine/threonine protein kinases that 
participate in several signal transduction pathways that function in the same cell and regulate 
different cellular events like cell proliferation, survival, motility, death and gene expression 
[48]. Our focus is the prominent RAS-RAF-MEK-ERK pathway or MAP Kinase pathway 
that is stimulated by growth factors [49, 50]. Activity of the MAPK pathway can also 
respond to integrin mediated cell adhesion to the ECM under specific conditions, specifically 
enhancing ERK activity [51]. Hence, integrins function together with growth factor receptors 
to activate the ERK-1/2 MAPK pathway [52J. 
The events of the conventional MAP kinase pathway, when activated in response to 
mitogens or the ECM, begin with the activation of Ras followed by the GTP bound Ras 
binding to Raf Kinase further leading to its cellular membrane translocation and finally 
phosphorylation and activation of Raf (MAPKKKinases). Active Raf then phosphorylates 
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and activates MEK (MAPKKinase) [17], which in turn activates extracellular regulated 
kinase {ERKl/2 (MAP Kinase)}. Active ERK plays a important role in adhesion dependent 
cell cycle regulation in response to activated integrins [53]. ERK1/2 lack a nuclear 
localization signal but can further translocate to the nucleus and phosphorylate transcription 
factors like Elk and CREB and thereby affect gene expression [54, 55]. 
There are different mechanisms by which the MAP kinase pathway can be affected and 
regulated by the integrins. We will see how these different mechanisms involve molecules 
participating in the MAP kinase pathway that are capable of being activated by integrins. 
Raf, unique from the other members, can be directly activated as a result of cell adhesion by 
integrins, which bypasses the need for Ras activation of this protein kinase [56]. Integrin- 
dependent adhesion affects both the members downstream of Raf, ERK and MEK. ERK, a 
key player in cell division, migration, and survival is affected at several checkpoints by 
integrin mediated anchorage-dependence [57] The different mechanisms proposed to explain 
the direct activation of ERK by integrins are tyrosine phosphorylation of FAK, activation of 
p21-activated kinase by its two regulators Rho-family GTPase Rac and SH2/SH3-adaptor 
protein Nck [58]. MEK seems to be a focal point in the cell's decision to grow and migrate 
and can also be regulated by integrin attachment. This activation does not involve the 
activation of Ras and Raf and can be initiated directly by integrins [15J. Regulation of MEK 
is important for cell adhesion as constitutively activated mutants of MEK in NIH3T3 cells 
can induce anchorage independent growth [59]. However, the exact molecular pathways by 
which MEK regulates these events have yet not been elucidated [60]. 
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The integrins and their cytoskeletal ligands also play a very important role in the 
nucleocytoplasmic distribution and trafficking of proteins that have a signaling potential. It is 
now being established that this control by cell adhesion molecules has a broad impact on the 
cell's ability to make decisions and also effects gene expression, thus establishing a 
communication between the ECM and the nucleus. For example the Jun activation domain 
binding protein (JAB)-1 binds to the X32 cytoplasmic domain of the lymphocyte function- 
associated antigen (LFA-1), a member of the X32 integrin family. JAB-1 is a co-activator of 
the transcription factor C-Jun and can enhance activation of AP-1 driven promoters [61]. Cell 
adhesion also especially effects the nucleocytoplasmic distribution of the MAP kinases [62]. 
Translocation of ERK from the cytoplasm to the nucleus requires its phosphorylation and 
homodimerization [63] and is also cell adhesion dependent [55]. The factors aiding this 
translocation in addition to the GTPase Ran, which is a inherent requirement [64], are still 
under study. However, once translocated to the nucleus, ERK is known to phosphorylate 
ELK-1, which in turn regulates the serum response factor (SRF) [65]. 
The MAPK pathway is activated in prostate cancer [66] and is believed to be highly 
involved in the development of breast cancer. Increased expression of activated MAP kinases 
has been demonstrated in various breast cancer tissues by using immunohistochemical 
techniques and enzymatic assays. Hormones like estradiol, progesterone and testosterone can 
bind to their membrane associated receptors and increase the activity of MAP kinases [67]. 
This pathway and its molecular components have been well established as playing a central 
role in regulating different aspects of tumor development. When activated, some members of 
the MAPK pathway individually have cell transforming potential [68]. Ras is a known 
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oncogene, implicated in the development of tumors like multiple myelomas [69]. Studies 
done with mutated Raf, have shown its correlation with tumor development experimentally 
and clinically [70]. In addition, active MEK has also been shown to cause cellular 
transformation [59]. Finally ERK1/2 were found to be constitutively active in many tumor 
cell lines. For example from cell lines derived from epithelial and granulose cell ovarian 
tumors. The expression of MAPK phosphatases-1 (MPK-1) was down regulated in these cell 
lines. Silencing ERK 1/2 protein expression by using RNA interference completely 
suppressed tumor cell proliferation [71]. ERK 1/2 have also been shown to mediate the 
increased invasiveness in prostate cancer cell invasiveness via the G-protein-coupled P2Y 
purinoceptor [72]. 
It is now well-established that the MAP Kinases play a role in regulating transcription of 
genes by acting on different transcription factors such as Elk- l , CREB, MEF2A, GATA-2, 
Rsk 1, AP-1 etc. [73] . For example, once activated, Rsks, a MAPK activated kinase, 
phosphorylates BAD (a proapoptotic protein) at serine 112 and CREB (CAMP response 
element binding protein) at serine 13 3 . Phosphorylation of BAD by Rsks suppressed BAD-
mediated apoptosis in neurons and phosphorylation of CREB promotes cell survival [74] . 
These transcription factor-dependent mechanisms mediated by the MAP kinase pathway play 
a very important role in the expression of several genes and thus regulate many physiological 
processes that involve cell decisions like apoptosis or survival. Because of its central role in 
regulating integrin signaling and gene expression, the MAP Kinase pathway is a focus of 
research for developing gene therapy interventions that target specific molecules such as Ras, 
Raf and MEK to accompany drug therapy [ 7 5 ] . 
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The FAK pathway is the second protein kinase signal transduction pathway under focus 
in our discussion. FAK is a 125 kDa protein tyrosine kinase containing a central catalytic 
domain flanked by N-terminal and C-terminal non-catalytic domains [76]. The 150 residue 
C-terminal domain also called the "activation loop" contains multiple binding sites for SH3 
domain containing signaling proteins like p130°as, GTPase activating protein GRAF for 
RhoA and Cdc42, HEF-1 and PI-3 kinase. The site of phosphorylation in this C-terminal 
regulatory region is the Ys'6is" [77] The C-terminal domain also contains the focal adhesion 
targeting (FAT) sequence, a stretch of 159 amino acids essential for the sub-cellular 
localization of FAK with integrins [78]. FAK is activated in many biological responses like 
cell motility, cell survival and FAK is known to play an active role in cell cycle progression 
[79-81]. Its activity is increased in many different human cancers like oral [82] and ovarian 
cancer [80]. Prostate carcinoma cell lines having overexpressed FAK show increased 
migration [83]. FAK is proposed to be involved in tumor invasion and metastasis [84]. 
The exact mechanism of FAK activation is still not well understood although several 
types of interactions and associations between certain adaptor proteins and FAK in response 
to integrins have been proposed [85]. The role of adaptor proteins is already well established 
in ECM regulated pathways and FAK plays a very important role in this ECM pathway 
regulation as we will see in the discussion that follows [86]. Adaptor molecules like Grb-2, 
c-Src bind to FAK in response to integrins that resulting in FAK activation [87]. A popular 
proposed mechanism for the activation of FAK is the autophosphorylation of FAK at 
tyrosine-397 in response to integrin activation. The tyrosine-397 is the site of association of 
two Src family kinases, the pp60src and the pp59fyn with tyrosine-phosphorylated forms of 
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FAK. In Src-transformed chicken embryo cells most of the pp125FAK was in the form of a 
complex with pp60src [88]. Once activated as a result of phosphorylation by FAK, Src can 
phosphorylate various signaling molecules such as Tensin, Paxillin, Cas, ERK, Ras, PI-3 
kinase etc. [89, 90]. Another hypothesis suggests that Grb2 is directly activated by FAK and 
Src through phosphorylation of Shc, an adaptor protein that gets activated once it binds to 
phosphorylated Tyrosine-397 of FAK [91]. Grb2 binds phosphor Shc [92, 93]. FAK can also 
colocalize with integrins at cell-ECM contact regions resulting in changes in its tyrosine 
kinase and phosphorylation state [94] and can also indirectly connect to betal integrins via 
molecules like paxillin and talin [95]. Activated FAK can also associate with other 
cytoskeletal molecules like p 130cas (Crk associated substrate), paxillin, Tensin, Rho, Cdc42, 
Ras and ERK from the MAP kinase pathway [96] [97]. FAK gets dephosphorylated by 
protein tyrosine phosphatases like PTEN [98] and SHP-2 [99], which effect the cells 
behavior directly by reducing its motility [100]. 
The relationship of FAK with the MAP kinase pathway is well established. FAK 
associates with adaptor proteins like Grb2 and Sos and activate members of the MAP kinase 
pathway like ERK1/2 in response to stress activation [101]. This interaction between FAK 
and ERK regulates the MAPK pathway in response to integrins [102]. For example over 
expression of FAK resulted in stimulation of ERK in response to integrin attachment to 
fibronectin and dominant-negative constructs of FAK in the same study inhibited ERK 
stimulation [103]. The relationship between ERK and FAK was further established when it 
was shown that FAK deficient cells were deficient in integrin mediated activation of ERK 
[ 104]. 
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The association of FAK with cancer has been attributed to is ability to control certain 
cancer phenotypes [105]. FAK is required for certain tumor cells to adhere to the substratum, 
to proliferate [106] and its overexpression is observed in oral [107], ovarian [80], breast, 
thyroid [108] squamous cell carcinoma of larynx [109] and prostate cancer [81]. FAK has a 
special predisposition for expression in certain invasive tumors [ 110, 111 ]. The direct effect 
of FAK over-expression is stimulation of cell spreading and migration [112], which is 
demonstrated in the cells of FAK-deficient mice that show reduced cell motility and 
enhanced cellular adhesions [113]. 
Finally we discuss the third pathway under our focus, the PI-3 kinase pathway. The PI3- 
kinase is a heterodimeric lipid kinase comprising of two subunits: an 85 kDa regulatory 
subunit containing SH2 and SH3 domains (p85) and a 110 kDa catalytic subunit (p110). This 
pathway plays a major role in cell survival processes in response to growth factor and 
extracellular attachment to the substratum like cell cycle progression, apoptosis and 
neoplastic transformation [114]. PI-3 kinase is expressed in invasive tumors [115J and its 
involvement is shown in the development of mammary carcinogenesis [116]. In cells 
expressing oncogenic variants of the abl proto-oncogene the activity of PI-3 kinase was 
increased [117]. PI-3 kinase is activated in response to ECM receptor activities like integrin- 
mediated attachment [118]. It associates with FAK in response to integrin attachment and 
phosphorylates FAK at Y397 [119]. Thereby, it regulates the ability of FAK to regulate cell 
migration. This interaction was demonstrated by doing site-directed mutagenesis studies. In 
these studies it was shown that creating a FAK point mutation proximal to Y397 abolishes 
the ability of PI-3 kinase but not Src kinase to bind to FAK. When these mutants were 
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overexpressed in CHO cells, FAK was unable to promote cell migration. They also further 
confirmed this finding by showing that the PI-3 kinase inhibitors LY294002 and Wortmennin 
inhibited FAK promoted migration in a dose dependent manner [120]. PI-3 kinase has also 
been known to be activated in response to E-cadherin receptors that are known to play a role 
in many biological processes similar to the ones in which integrins are involved like cell 
growth, development and differentiation [ 121 ]. 
Activated PI-3 kinase phosphorylates the membrane lipid, phosphatidylinositol-4, 5- 
bisphosphate (Ptdlns-4, 5-P2), to form phosphatidylinositol-3, 4, 5-tri-phosphate (PtdIns-3, 4, 
5-P3) [ 122] . Inositol phosphates activates other enzymes [ 123] . For example p70S6 kinase is 
activated by PDK1, which in turn gets activated by IP3,4 [124]. PKB/AKT is directly 
activated by IP3,4 and other IP phosphorylated derivatives [ 125] . Another important 
molecule that is phosphorylated by PI-3 kinase is the ERKl/2 from the MAP kinase pathway 
[ 126, 127] . In addition to its activation of ERK 1 /2, PI-3 kinase also plays an important role in 
activation of Ras, another member of the MAP kinase pathway and can affect the ability of 
Ras to mediate transformation of cells [128, 129]. Hence the PI-3 kinase pathway, once 
activated, can have its effects independently or work by regulating other pathways like the 
MAP kinase pathway. 
ECM enzymes: matrix metalloproteinases 
The matrix metalloproteinases (MMPs or matrixins) are the most important enzymes 
involved in the ECM degrading events during all tissue remodeling processes [130]. These 
are multidomain, zinc and calcium dependent proteases whose substrates are certain ECM 
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molecules and the inactive MMP zymogens [ 131 ]. The known members of the MMP protein 
family include the Collagenases: {Collagenase 1 (MMP-1), Collagenase 2 (MMP-8), 
Collagenase 3 (MMP-13), Collagenase 4 (MMP-18)}; Gelatinases: {Gelatinase A (MMP-2), 
Gelatinase B (MMP-9)}; Stromelysins: {Stromelysin 1 (MMP-3), Stromelysin 2 (MMP-10), 
Stromelysin 3 (MMP-11)}; Membrane Type Metalloproteinases (MT-MMPs): {MT1-MMP 
(MMP-14), MT2-MMP (MMP-1 S), MT3-MMP (MMP-1 ~, MT4-MMP (MMP-1 ~, MTS- 
MMP (MMP-24)}; Others: {Matrilysin (MMP-~, Metalloelastase (MMP-12), Enamelysin 
(MMP-20); Not named (MMP-19), and not named (MMP-23)}[132]. The MMPs are 
produced by a variety of cell types and their production is regulated by growth factors and 
cytokines that activate the genes via downstream transcription factors like AP1, NFkB etc. 
All MMPs are secreted as latent zymogens that are inactive because of the binding of the 
conserved cysteine (cys-73) to a zinc molecule [133]. The mechanism of activation, which is 
considered universal for most of these enzymes, is termed the "cysteine switch" and, as 
demonstrated with HFC (human fibroblast collagenase), involves the dissociation and 
replacement of the cys-73 ligand of the zinc molecule with water, thus turning the inactive 
zinc to an active form [134]. Generally pro-MMPs and tissue inhibitors for MMPs (TIMP's) 
are secreted together and this maintains the delicate balance of the cell in its physiological 
state [135]. The pro-MMP's can be activated in vitro by various means like action of 
different proteases like trypsin, chymase and plasmin or of other MMPs like MMP-2, MMP- 
7, MMP-13 and MMP-3 and also by the action of different proteolytic mechanisms 
functional at cell-surface, intracellular or extracellular level. In-vivo their regulation occurs at 
different levels ranging from gene transcription to enzyme activation and inhibition. 
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The MMPs play an active role in tissue remodeling events such as wound healing [ 136], 
trophoblastic implantation [137], embryogenesis [138], bone resorption and morphogenesis 
[ 139]. MMPs have also been further implicated in pathological processes [ 140] like arthritis 
[ 141 ], multiple sclerosis ,osteoporosis, Alzheimer's [ 142] and tumor metastasis during 
cancer [143]. The physiological roles of the MMPs will be discussed in detail in the 
following discussion. Almost all the events during wound healing are directly or indirectly 
interdependent and related to the proper functioning of the MMPs like cell migration, 
angiogenesis, degradation of provisional matrix consisting of fibrin and plasma proteins and 
remodeling of newly formed granulation tissue [144-146]. During angiogenesis MMPs help 
endothelial cells penetrate several components of the ECM like the subendothelial basement 
membrane, fibronectin containing interstitial matrix and laminins that form a integral part of 
the extracellular matrix [147]. MMP's like MMP-9 and MMP-13 play a important role in 
skeletal tissue remodeling by recruiting cells like osteoclasts, chondroclasts, osteoprogenitors 
and endothelial cells necessary for bone morphogenesis [148]. The MMPs have also been 
shown to play a role during reproductive events such as ovulation, corpus luteum 
formation/regression, implantation, lactation [ 149] and mammary and uterine involution 
[138, 150]. Maintaining the correct balance between ECM production and degradation during 
tissue remodeling is very important because excessive production can lead to formation of 
keloids (hypertrophic scars) and excessive degradation can lead to formation of chronic 
ulcers [151]. 
MMPs are expressed in numerous pathological conditions including collagen and bone 
disorders like osteoporosis, osteoartheritis, chondrodysplasias, osteogenesis imperfecta, 
18 
certain renal disorders, cancers and other diseases [152] [153]. During cancer MMP's in 
addition to playing a role during invasion and metastasis, now MMP's are known to play a 
role in cancer initiation and promotion [154]. Expression of collagenase in transgenic mice 
increases its susceptibility to treatments with initiator (7,12-dimethyl-benzaanthracene) and 
promoter (12-O-tetradecanoylphorbol-l3-acetate) and subsequent development of skin 
carcinogenesis [155]. Upregulation of various growth factor signaling pathways during 
cancer promotion can lead inturn to the activation of different mmp genes. For example, in 
colon cancer cell lines EFG upregulates the expression of MMP-7 via the activation of PEA3 
transcription factor [156]. Helicobactor pylori strains that posses the cag pathogenicity island 
(cag+) have a greater risk of distal gastric carcinoma formation. Differential expression of 
mmp-7 was seen from H. pylori cag (+) isolates from human gastric mucosa and this was 
suggested to cause the preponderance in H. pylori cag (+) persons to the development of 
gastric carcinomas [157]. They are secreted by cancer cells and their surrounding normal 
stromal cells and can degrade ECM and inactivate proteinase inhibitors. All these abilities 
have established them as playing a key role in cancer development [158]. The roles 
attributed to MMPs include degrading ECM, digesting basement membranes and invading 
blood vessels, when combined together results in leading to rapid tumor metastasis [159, 
160]. 
Generally, MMPs are expressed in cells that are differentiating [161] or that demonstrate 
an invasive phenotype [162, 163]. Although their patterns of expression must be very strictly 
regulated, we do not know much about their expression patterns and how expression is 
regulated in vivo [164]. Stromelysin-2 is upregulated in normal wound healing in response to 
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growth factors [165]. MMP-12 is expressed by tumor cells in skin cancer [166], and MMP-3, 
7,10, 11 and 14 and TIMPs-1, 2, 3 and 4 were expressed in head and neck squamous cell 
carcinoma and not the surrounding tissue [167]. MMP expression can directly affect the 
development of a pathological condition or could indirectly contribute towards it. For 
example MMP-11 (stromelysin-3) even though not directly associated with tumorogenicity 
studies has been shown to increase the availability of growth factors to the cells [168]. The 
expression of certain MMPs like stromelysins and gelatinases is increased in tumor 
metastasis and progression [169]. 
The MMPs play multiple roles in tumor invasion and metastasis and numerous MMPs are 
involved in ECM remodeling events with the pattern of expression being different for 
different MMPs [170]. For example, MMP-9 is expressed during bone development, the hair 
follicle growth cycle, neurogenesis, and tissue repair [171] [172] [173]. It is also expressed 
in gliomas, especially the malignant and invasive types [174]. MMP9 activation also 
enhances tumor cell intravasation [175] and tumor progression and invasion [176, 177]. The 
94-kDa type IV collagenase is expressed by eosinophils during basal cell carcinoma 
development [ 178] and in wound healing by basal keratinocytes [ 179, 180J. Expression of 
matrilysin, collagenase and stromelysinl is increased in gastrointestinal tumors [181]. MMP- 
7 expression is increased during colon cancer [182], MMP-13 expression was seen in 
carcinoma of the urinary bladder [183] and MMP-3 expression is associated with 
development of mammary carcinoma [184]. Stromelysin-1 acts as a natural tumor promoter 
[185] and expression of the rat homologue of stromelysin, transin, is correlated with tumor 
progression [186]. All MMP's were found activated and expressed in samples from breast 
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cancer [187] . MMPs are also known to play a important role in recruiting osteoclasts and 
thus making the bone the most common site for secondary carcinoma development [188]. 
The integrins and their ligands, like fibronectin, regulate the expression of several MMP 
genes [189]. Alphal and alpha2 integrins are involved in the development of invasive 
behavior of mouse mammary carcinoma cells through the regulation of stromelysin-1 [30]. 
MMP-2 has been localized to the surface of tumor cells and shown to be associated with the 
integrin alphaVbeta3 [190]. Integrin alpha2betal, through its interaction with collagen 1, 
regulates functions like cell adhesion and invasion in osteosarcoma [29] cell line. 
A1pha5betal and alpha4betal integrins regulate MMP expression cooperatively in fibroblasts 
[191]. Type IV collagenase expression was induced by using anti-integrin antibodies in 
keratinocytes [192]. Integrin alpha2betal regulate MMP-1 gene expression [193]. 
The MAPK pathway is believed to regulate MMP gene expression through activation by 
the integrins [194, 195]. For example in human skin fibroblasts induction of MMP-13 along 
with activation of MAP Kinase pathway was seen in response to collagen [196]. Membrane 
type 1 MMP regulates activation of MAP kinase pathway in response to collagen [197]. 
Activation of MAP kinase pathway, especially MEK, was shown to be the focal point in the 
activation of MMP-2 [ 198] and MMP-9 genes [ 199]. In ovarian cancer cells MMP-9 was 
activated via the MAP kinase pathway [200]. 
From the studies above we can say that the role of MMPs and their inhibitors in relation 
to normal and abnormal functioning of our body is very important and identifying molecules 
that could be participating in this regulation will be very helpful to broaden our 
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understanding [201]. Now, therapeutically and clinically, the focus on MMPs has increased 
with the development of new MMP inhibitors. Some inhibitors are already being used as 
drugs in different diseases like certain connective tissue disorders [202], while others are still 
in different phases of clinical trials [203]. Some of them are being used as drugs in cancer as 
supplemental therapy and still others are undergoing development [204] [205]. 
Anchorage dependence 
Cells respond to growth factors and extracellular matrix (ECM) individually or in 
combination with each other through their receptors. Integrins play a very important role in 
this cell-ECM attachment along with a specific condition called anchorage-dependence of 
growth [206]. Normal cells are anchorage dependent and when these normal cells are 
detached, they undergo anoikis, which is apoptosis caused by loss of adhesion to the 
substratum [207]. Various ECM receptors like integrins play a very important role in the 
maintenance of anchorage dependence [208]. Under normal conditions the important 
mitogenic signal transduction cascades like MAP Kinase, PI-3 Kinase, Src Kinase and Focal 
Adhesion Kinase require integrin-mediated cell adhesion to the substratum in order to be 
regulated and be functional [209]. Some molecules from these pathways have the capability 
of overcoming the need for substrate attachment under certain conditions and are capable of 
inducing anchorage-independent growth [210]. This property becomes especially important 
in tissue remodeling processes because the cells involved in these events show increased 
deviation from their normal anchorage requirement and by becoming anchorage independent 
they then acquire the ability to move from their original position to different areas. This is 
also very important in relation to conditions like cancer. 
22 
Tumor cells have the ability to be fully functional in suspension, overcome anchorage 
dependence or become anchorage-independent. Hence tumor cells remain viable and initiate 
various signal transduction pathways even while detached from the ECM [211]. Unraveling 
the complexities of this phenomenon will give us a better idea about the role it plays in tissue 
remodeling processes like wound healing and diseases like cancer and will give the clinician 
abetter tool to treat these diseases. Anchorage can also effect the distribution of transcription 
factors between the cytoplasm and the nucleus. Outlining the key players like the receptors, 
the signal transduction pathways, transcription factors and genes that are regulated in 
response to anchorage dependence would be a big contribution towards conceptualizing and 
developing new therapies [212]. It would outline and establish certain molecular markers 
that could be used for new clinical and therapeutic intervention strategies in order to control 
and cure diseases like cancer. 
Mitogen regulated protein/proliferin's 
Mitogen regulated proteins/Proliferins (MRP/PLF's) are a family of glycoproteins that 
are secreted by cells in response to mitogen/growth factor stimulation [213]. MRP/PLFs can 
be produced by the following mouse cell lines: BALB/c 3T3 [214] [215], BNL [216], Krebs 
ascites carcinoma cells [217], IOTl/2 cells [218J and Ehrlich ascites carcinoma cells [219]. 
Swiss 3T3 cells make mainly PLF1 [220]. These cell lines secrete PLF1 in response to the 
following mitogens/growth factors: serum [213] [216], phorbol esters [221], basic fibroblast 
growth factor (bFGF) [213], epidermal growth factor (EGF) [222], transforming growth 
factor-alpha (TGF-alpha) [223]. The apparent molecular weight of MRP/PLF when 
unglycosylated is ~22kDa and when glycosylated is ~34 kDa [213]. The MRPlPLF's are 
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members of the Prolactin-Growth hormone superfamily [217]. There are four to six mrp/plf 
genes [224] [225] [226] and four mrp/plf cDNAs have been cloned. These are plfl [214] 
[217], p~ [227], mrp3 [216] and mrp4 [220]. The amino acid sequences of the proteins 
encoded by these genes are 91-98%identical and similar to each other [225]. 
Three promoters have been cloned for the three mrp/plf genes; mrp3, plfl and mrp4. The 
promoters of these three genes are very similar to each other between positions —576 to +65 
with plfl promoter and mrp4 promoter being 97% identical to each other [226] and mrp3 
being 98.4% identical to p1f42 and 97.4% identical to p1fl49 [225]. These promoters contain 
many active basal as well as regulatory transcriptional elements that may have a potential 
effect on mrp/plf gene expression in vivo like the TATA box, AP 1 transcription factor 
consensus binding site [225], Sph elements [228], composite glucocorticoid response element 
(cGRE) [229] and several GATA recognition motifs like GATAG, GATT and GATAA 
[230]. 
Despite the similarities in promoter sequences, different mrp/plf's are expressed during 
various physiological events. All mrp/plfs (plfl , mrp3 and mrp4) are expressed in vivo in the 
mouse placenta in the trophoblastic giant cells [231], with the expression being maximum at 
9-13 day of gestation. This period of expression is also the period of rapid placental growth 
[232]. Plfl and mrp3 are also expressed in the embryo and PLFI and/or MRP3 proteins are 
found in the amniotic fluid and some parts of the embryo during development [233]. PLF1 
and/or MRP3 but not MRP4 are found in the maternal blood. This maybe because MRP4 is 
rapidly degraded or because it cannot cross into the maternal blood stream from the placenta 
[232]. Plfl is expressed in the stomach and small intestine. Mrp3 is expressed during wound 
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healing in adults and the protein is found in the suprabasal keratinocytes at the wound site, in 
the outer root sheath of the hair follicle during the hair follicle cycle (late anagen phase) and 
a small amount is expressed in the small intestine [234]. Mrp4 is expressed mainly in the hair 
follicle in late anagen phase of the adult mouse tail and ear [220]. Mrp/plf's have also been 
found in fetal heart and vertebral column [235]. 
Mrp/plf's bind to two cell surface receptors: The mannose-6-phosphate receptor in 
maternal and fetal liver as well as placental membranes [236, 237] and a second receptor 
from murine mammary and uterine preparations that has not been cloned [238]. The two 
proposed physiological functions for the MRP/PLFs are as growth factors and angiogenesis 
factors. MRP/PLFs are proposed to stimulate uterine and placental growth and, being 
produced by the placenta, thereby be a means of signaling between the placenta and uterus 
[238]. PLF1 has also been shown to stimulate endothelial angiogenesis and 
neovascularisation [239, 240]. 
Regulation of gene expression by the FGF's 
Growth factors regulate cellular functions like cellular differentiation, proliferation and 
growth during embryogenesis. Their coordinated regulation in vivo plays a very important 
role in the development of the normal adult human being. Growth factors achieve their 
effects by activating signal transduction pathways that ultimately result in the changed 
expression of downstream genes and the proteins that they encode. Hence, to understand the 
physiological roles of the various growth factors it is important to identify the signal 
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transduction pathways and the key players involved in the regulation of their expression 
[241 ]. 
The fibroblast growth factor family is comprised of the 26 members identified to date. 
Some of them are as follows: acidic FGF (FGF-1), basic FGF (FGF-2), int-2 (FGF-3), k-FGF 
(FGF-4), FGF-5, FGF-6, keratinocyte growth factor (FGF-7), FGF-8, FGF-9 etc. These 
growth factors are conserved among species and are encoded by distinct genes. Several 
members of the FGF family play a role in regulation of embryonic development [242, 243], 
differentiation of cellular phenotypes during muscle and limb development [244] and 
transcription of myogenic genes [245, 246]. FGF's are also expressed in the developing [247] 
and adult central nervous system [248] and have been described as being involved in 
angiogenesis during wound healing [249]. Several FGF's like FGF-3, FGF-4 and FGF-5 can 
behave as oncogenes and have transforming potential in vitro [250]. The expression pattern 
of each FGF differs during mammalian development, for example while FGF-4 is expressed 
during the early 4 cell stage, blastocyst stage and also during later stages of development 
[244], the other isoforms like FGF-3 and FGF-5 are expressed primarily in parietal and 
visceral endoderm before gastrulation until mesoderm formation [251] [252]. 
Evidence from numerous studies indicates the presence of several regulatory fragments 
that transcriptionally regulate FGF expression in the cells. FGF-4 is known to be regulated by 
a putative octamer-binding site along with other cis-regulatory elements [253], FGF-3 is 
regulated as a result of transcription from three possible promoter regions [254] while FGF-2 
has 5 potential SP-1 binding sites consisting of the functional core of the promoter and one 
potential AP1 site [255]. 
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The FGF's execute their biological and physiological functions through interactions with 
multiple FGF receptors [256] of which 5 different receptor genes have been cloned and 
sequenced including FGFR-1 (Flg, Cek-1) [257], FGFR-2 (Bek, K-SAM, TK-14, Cek-3) 
[258] [259J, FGFR-3 (Cek-2) [260, 261], FGFR-4 [262] and FGFR-5 (Flg-2) [263] [264]. 
Alternative splicing has been known to generate several isoforms among these five receptors 
[265]. These receptors are heavily glycosylated and consist of an extracellular domain, short 
transmembrane domain and a cytoplasmic domain. Several of these receptors and their splice 
variants bind to the following ligands like FGF-1, FGF-2, FGF-4, FGF-5, FGF-6, FGF-7 
with variable specificity [266] but receptors for FGF-3 have not yet been identified. The 
importance of FGF receptors to fetal development is evidenced by the observation that many 
human birth defects have been attributed to mutations in these receptors like craniocynostosis 
(premature fusion of the cranial sutures) [267] and other skeletal abnormalities like 
achondroplasia [268], hypochondroplasia cnd thanatophoric dysplasia [269]. 
FGF binding to its respective receptor leads to dimerisation, activation of the receptor's 
tyrosine kinase activity [270] and receptor autophosphorylation [271 J. The main sites for 
FGF receptor autophosphorylation are two tyrosine residues, Ty-766 and Ty-653 [272, 273]. 
Activated FGF receptors can phosphorylate downstream substrates like PLC-yl and PI-3 
kinase. Upon activation PLC-yl hydrolyses phosphotidylinositol that produces two-second 
messengers; inositol 1,4,5-triphosphate (IP3) and diacylglycerol (DAG) [274]. PI-3 kinase 
(p85) phosphorylates the D-3 position of inositol resulting in the production of a novel 
phospholipid, the phosphotidyl-inositol-3-phosphate (PI3P) [275]. The FGF receptors can 
phosphorylate other cellular proteins like Raf-1 [276], interact with membrane-associated 
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proteins like heterotrimeric G-protein [277] and increase transcription of genes like c fos 
~2~g~. 
There are different forms of bFGF (also called FGF-2) with molecular weight ranging 
from 18.5 to ~24kDa due to the presence of different translation start sites [279-281]. bFGF 
can be found in almost all cell types, organs, tissues [250]. bFGF regulates a variety of 
functions at different stages of development ranging from induction of ventral mesoderm in 
embryos, neovascularisation during fetal development to adult processes such as various 
tissue remodeling events like wound healing [282]. bFGF also regulates basic cell functions 
like differentiation, proliferation, motility and migration [281, 283]. 
The effects of bFGF are mediated by way of the transmembrane FGF receptors and 
the heparin-sulphate proteogycans receptors [284]. There are several genes that are regulated 
by bFGF and the mechanism adopted differs greatly depending on promoter and cell type 
[285]. The rat osteocalcin gene promoter is activated by bFGF in MC3T3-E1 osteoblast cells 
by a segment spanning from —144 to —138 (GCATCA) and called the osteocalcin fibroblast 
growth factor response element (OCFRE). This activation is very specific for bFGF and other 
growth factors like EGF, PDGF, TGF-beta and IGF-1 do not activate the OCRE. In order to 
confer bFGF responsiveness two or more copies of the OC promoter fragment —154 to —113 
that allow 42 by between each of the three tandem repeats of OCFRE upstream of a minimal 
OC promoter are required. The proteins binding to OCFRE from nuclear extracts prepared 
from bFGF stimulated MC3T3-El cells are very specific for this sequence and AP-1 is not 
part of this complex. This element is regulated by phosphorylation as suggested by its 
activation by okadaic acid, an inhibitor of phosphatases [286] [287]. 
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The AP1 element is downstream from FGF in many signal transduction pathways. For 
example, the human interstitial collagenase (MMP-1) is modulated by bFGF in many 
different cell types like the MC3T3-El osteoblast cells [288], in human smooth muscle cells 
[289] and in NIH 3T3 cells [290]. The human collagenase promoter consists of a bFGF 
response element containing an AP-1 element (TGAGTCA) as well as an Ets element 
(AGGATG). Their locations are between —100 to —61 by upstream of the start site and both 
are proposed to act together in regulation of transcription. This element is regulated via a Ras 
and the MKP2 regulated MAP kinase pathway in MC3T3-El cells [288]. 
The rat prolactin gene is also regulated by bFGF in GH4 rat pituitary cells through two 
Ets elements located between —212 and -96. The bFGF site on the prolactin gene is 
overlapping with two other elements; a Ras response element and also an insulin response 
element but each is known to bind to different proteins and act through different signal 
transduction pathways. The MAP kinase pathway is involved in the regulation of rat 
prolactin by bFGF but the p2lras and Raf-1 kinase are not involved. The transcription factors 
involved in this regulation are yet to be identified [291]. 
The proenkephalin gene promoter is regulated by bFGF and c-AMP together by a Ras 
dependent pathway through the CRE-like DNA regulatory element (CRE-2). The CRE-2 
binds to CREB/ATF proteins, which regulate transcription by a pathway that depolarizes 
cAMP and Ca++ in the process [292]. The syndecan-1 gene is regulated by bFGF via the 
FGF-inducible response element (FiRE). This element is 170 by long and contains five DNA 
motifs that can bind to different proteins including an AP2 related protein, two FGF- 
inducible Fos-Jun heterodimers, an upstream stimulatory factor and an 46 kDa transcription 
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factor [293]. Certain other bFGF-responsive elements have also been identified. For example 
in cardiac muscles the skeletal alpha-actin promoter is regulated by bFGF via an SRE-1 
element. [294]. 
The structure, receptors and functions of different FGF's are well documented but the 
role of different FGF's, especially bFGF, in regulating the expression of many genes is still 
not fully established [295 ] . One area that merits more investigation is the mechanism by 
which the various FGF's regulate gene expression through the activation of signal 
transduction pathways. The key players that are involved in the transcriptional regulation 
genes downstream from FGF's and the mechanism adopted by them is till now not clearly 
outlined. Our study is expected to contribute to identifying the specific signal transduction 
pathways involved in the transcriptional regulation of genes by FGF. 
The AP-1 transcriptional element 
Activator protein-1 (AP-1) is a very well established transcription factor that was first 
identified as a group of proteins binding to the TPA-responsive elements (TRE) in phorbol 
12-o-tetradecanoate-l3-acetate inducible (TPA) genes [296-298]. It contains several bZIP 
(basic region-leucine zipper) domain protein dimer complexes comprising of Jun (cJun, Jung 
and JunD) and Fos (c-Fos, FosB, Fra-1 and Fra-2). These subunits interact with other 
proteins like the Jun dimerisation partners (JDP1 and JDP2) and the activating transcription 
factors (ATF's: ATF2, LRF/ATF3 and B-ATF. The AP-1 subunits can form homodimers or 
heterodimers and bind to the AP-1 binding site, the TPA-response element (TRE) and also 
the cAMP response element (CRE) from promoters of many cellular genes [299]. AP-1 can 
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also regulate basal as well as inducible transcription from various genes including 
collagenase, IL-2, c jun, fos, Bcl-3 [298, 300, 301]. 
AP-1 constituent proteins are differentially expressed and activated in response to 
physiological and pathological stimuli like growth factors, inflammatory cytokines, antigen 
binding, environmental signals like cellular stress, UV and ionizing radiation, certain 
oncoproteins like v-src and Ha-Ras [302, 303]. Reports have shown that AP-1 activation 
plays a very important role in many biological and pathological processes like cell 
proliferation, survival, apoptosis, neoplastic transformation and tumor formation [304, 305]. 
AP-1 plays a vital role in the above processes by regulating the expression of certain cell 
cycle regulators like cyclin D 1, glucocorticoid receptor, p53, p21 cip/waft ~ p 19A~ and p 16 
[305]. AP-1 gets activated by various mechanisms like autoregulation by its different 
subunits [306], through interactions with other proteins like maf proteins (v-Maf, c-Maf, 
MafB, MafF, MafG, MafK) [307], co-activators like Jun activation domain binding protein 
(JABl) [308, 309] and also by phosphorylation by protein kinases like the MAP kinases 
[310, 311]. 
The AP1 binding site (TRE) is also found to be an integral part of the mrp3 promoter 
region located at -231 to -225 [225]. Phorbol esters can stimulate transcription of the mrp3 
gene in cultured cells (CHO, L, IOTI/2 cells) and in placenta [221]. A 31 by region that 
includes an AP-1 binding site, a glucocorticoid receptor-binding site and a SV40 SphI 
element is involved in this activation. Mutation of any of these two elements completely 
attenuated the phorbol ester induction. Furthermore 3 copies of the 31 by region introduced 
upstream of a minimal thymidine kinase promoter was capable of inducing transcription in 
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response to phorbol esters [229]. This sequence was termed as the "composite" 
glucocorticoid response element (cGRE). In response to glucocorticoids in L cells, CHO cells 
and HeLa cells, this element can have a positive as well as negative regulatory effect. This 
element can be selectively bound in vitro to the glucocorticoid receptor as well as the AP-1 
transcription factor. In the presence of cJun-cJun homodimers at the AP-1 site this element 
stimulates transcription from a minimal promoter in response to glucocorticoids. But if cJun- 
cFos heterodimers are present instead of cJun-cJun homodimers then a negative response is 
elicited in response to glucocorticoids [312]. PKC's induce cFos and cJun and it was shown 
that inhibiting PKC's did not have any effect on the bFGF regulation of mrp3 [313]. These 
experiments suggested that AP-1 is not involved in regulating mrp3 in response to bFGF 
stimulation. But AP-1 does regulate the plfl promoter in response to serum hence the AP-1 
activity was also analyzed in our studies described here and its role established. 
Basic-fibroblast growth factor response element (FRE) 
bFGF also regulates the expression of the mitogen regulated protein/proliferin 
(mrp/plf's) gene, mrp3. Expression of the mitogen-regulated proteins (MRP/PLF's) is 
regulated by bFGF in cultured cells and bFGF receptors are shown to be present in tissues 
where these genes are expressed. Mrp/plf mRNA's begin to increase around 8-lOh and peaks 
at 12-16h in response to bFGF in 3T3 cells [314]. Interestingly only mrp3 is transcriptionaly 
activated by bFGF while the plfl and mrp4 promoters are not, although all three promoters 
share 97% homology in sequence [315]. This identity was utilized to further our 
understanding of the mechanism of bFGF regulation of gene expression. Comparisons of the 
three promoters for mrp/plf were carried out to determine what part of the mrp3 promoter 
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was responsible for regulation of mrp3 transcription by bFGF. Truncated promoters were 
analyzed using a chloramphenicol acetyl transferase reporter assay. After a series of 
truncation experiments a region within the first 353 by between —186 and —167 by in this 
promoter was identified that binds to nuclear factors from different cell lines. This identified 
region was named as the "bFGF-responsive element" (FRE). This FRE sequence was found 
to be unique and not similar to any other reported elements. The FRE was shown to be 
transcriptionally active in a TK fusion promoter and to respond to bFGF. Therefore it was 
established as a possible new transcriptional element [313] [315]. 
The FRE sequence was also found in the promoters of many bFGF- regulated genes. 
These are as follows: MMP family members; stromelysin-1 (mmp-3), gelatinase A (mmp-2), 
collagenase type 1, gelatinase B (92 kDa type Iv collagenase, mmp-9) and other proteases; 
cathepsinL, cathepsin B, tissue plasminogen activator. Furthermore the protease genes not 
regulated by bFGF like elastase, metalloelastase, trypsin, and chymotrypsin did not contain 
FRE or FRE-like sequences [313]. This was a significant finding because not only are mmp 's 
expressed in the same tissues as mrp/plf's but also the proteins expressed by these mmp genes 
are involved in similar physiological tissue remodeling events like wound healing. 
mrp3 is regulated transcriptionaly in response to bFGF. It was proposed that FRE could 
be the new transcriptional element that takes an active part or is responsible for the regulation 
of genes like the mrp3 and certain mmp 's in response to the growth factor, bFGF. Hence this 
finding was an important step towards elucidating the mechanism by which bFGF regulates 
transcription. 
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FRE-binding Protein (FREBP) 
FRE, the response element from the proximal promoter of the mrp3 gene binds to one 
or more nuclear factors derived not only from cell lines like NIH 3T3 cells (mouse), CHO 
cells (hamster) and HeLa cells (human) but also from tissues like the placenta (day 11) and 
fetus, regions where mrp3 is seen to be highly expressed. Nuclear extracts from maternal 
liver do not bind the FRE. These nuclear factors) preferentially bind to the FRE over the 
other similar sequences from the p1f42 and p1f149 promoters. Interestingly substitution of 
just one base pair in the FRE at positions —173 and —181 markedly changes the FRE's ability 
to compete for binding to these nuclear factor(s). The results from EMSA studies showed a 
single band with slower mobility in nuclear extracts. This binding of FRE with its nuclear 
proteins was not bFGF dependent and was the same from both bFGF stimulated and the 
unstimulated cells. In order to establish the segment from FRE oligonucleotide that 
specifically binds proteins, competition assays were performed using nuclear extracts from 
3T3 cells. The results of the competition assay showed that an oligomer (-179 to —162bp) that 
contained the 3' 2/3 of the FRE oligonucleotide competed successfully over the oligomer (- 
191 to —174) containing the 5' 2/3 of the FRE oligonucleotide for the nuclear proteins. This 
outlines the region from the FRE that the nuclear proteins were binding [313]. 
Certain transcription factors that were potential candidates for binding to the 
FRE and for forming a complex were ruled out as the FRE-binding transcription factor by the 
following experiments. Expression from the p1f42 promoter in L cells and the expression of 
MRP/PLF protein and mRNA in 3T3 cells increase in response to phorbol myristate acetate. 
Since the serum induced expression from p1f42 in L cells is regulated through the AP-1 
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transcription factor [228] and bFGF is known to increase the expression of cFos and cJun 
[316], the FRE-nuclear protein complex was examined to exclude the role, if any, of other 
transcription factors in the formation of this complex. The AP-1 recognition element was not 
found in the FRE oligonucleotide sequence and it was also tested whether Fos and Jun were a 
part of the of FRE-proteins) complex. The AP-1 oligonucleotide did not compete for the 
nuclear factors binding to the FRE oligonucleotide sequence and neither did the addition of 
anti-Fos/ anti-Jun antibodies alter the relative mobility of the FRE-protein complex. But the 
addition of anti-Fos and anti-Jun antibodies did produce a supershift of the AP-1-protein 
complex. These studies established that Fos and Jun are not components of the complex 
formed by the FRE with nuclear proteins. The FRE also contains a potential GATA site and 
GATA transcription factors, known to be important for the expression of the mrp/plf genes in 
the placenta [317]. Hence though these transcription factors could possibly bind to the FRE. 
But it was seen that these GATA factors were part of the x'2/3 of the FRE that did not 
compete for the binding of the FRE-protein complex thus ruling these transcription factors 
out for playing any role in the regulation of mrp3 expression via the FRE [315]. 
To determine if the binding of proteins) to the FRE is regulated by bFGF, one 
and three tandem repeats were linked upstream of the minimal mrp3 promoter —81 to +65- 
CATbasic reporter gene and were stably transfected into Swiss 3T3 cells. The addition of 
three tandem copies of FRE upstream of a basal TK promoter resulted in activation in 
response to bFGF [313]. The apparent native molecular weight of this FRE-protein complex 
was determined by the method of Hendrick and Smith [318] in 3T3 cells. To do this, the 
FREBP-FRE complex was resolved through nondenaturing polyacrylamide gels made of 
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different concentrations of acrylamide. The relative mobility of the standard proteins in the 
complex and the shifted bands was plotted versus percent acrylamide on a log scale. The 
slope of the lines from the standard proteins was further plotted against their MW and this 
standard curve was used to estimate the MW of the FRE-protein complex. The apparent MW 
of FRE-FREBP complex was estimated at ~60 kDa. Then the proteins) bound to FRE were 
covalently linked by UV cross-linking to FRE (-186 to —167 oligonucleotides of mrp3 
promoter) and run on SDS-PAGE where 2-3 bands were detected. Proteins ranging from 32 
to 37 kDa were identified after subtracting the MW of the oligonucleotide (~23-28 kDa) 
[313]. 
Further characterization of the FRE-protein complexes cross-linked by UV- 
irradiation was done. These experiments resulted in the conclusion that the average apparent 
molecular weight of FREBP is ~ 32-34 kDa. The FRE element linked in three tandem repeats 
upstream of the minimal thymidine kinase CAT reporter gene was shown to be bFGF 
responsive, hence it was proposed that the protein binding to this FRE is a bFGF activated 
protein. This nuclear factor that binds the FRE was termed as the Fibroblast growth factor 
response element binding protein (FREBP) [313]. It was hypothesized that this transcription 
factor that binds to the FRE element from the mrp3 promoter regulates mrp3 gene expression 
in response to bFGF. 
Transcription factors in general can either be activated in response to certain 
stimuli or may be constitutively expressed in the cell [319]. Expression of the FREBP is 
tissue- specific because it was not expressed in the maternal liver but was detected only in the 
placenta and fetus, and was especially prevalent in proliferating tissues corresponding to the 
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developmental period of expression of the mrp3 gene. Furthermore, FREBP activity was 
found in cells of several species including 3T3 cells from mouse; CHO cells from hamster 
and Hela cells from humans. FRE-like sequences from different MMP family members like 
stromelysin (mmp3: human and rat), and collagenase (mmpl: mouse) were capable of 
binding proteins in the nuclear extracts from above cell lines and of creating the same 
mobility shifted band as with the FRE. Also, successful competitive binding was observed 
from the previously mentioned MMP family member sequences for the proteins binding to 
the FRE and also for proteins binding to the FRE like sequences [313]. Hence, it was 
hypothesized that the same FREBP proteins) could be binding to the FRE-like elements 
from the matrix metalloproteinase genes as binds to the FRE in the mrp3. 
Based on the observation that the proteins binding the FRE and the FRE-like 
sequences from the mmp family members were competed off in a similar way by the FRE 
oligonucleotides it was suggested that it could be the FREBP that is binding to these FRE- 
like sequences from the mmp family members. It was also proposed that this FREBP might 
be the transcription factor that coordinately regulates the expression of mrp3 and certain 
other FRE-containing genes from the mmp family members in response to bFGF. Thus, 
identifying and establishing the mechanism by which the FREBP is regulating these genes 
and identifying the pathway that is involved in the regulation of mrp3 by FREBP in response 
to bFGF will be very important. The key molecules that participate in these pathways will 
provide us information on the mechanisms) that play an important role in helping the cell 
become anchorage independent or sometimes also mitogen independent. This would be a 
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very important step in characterizing the regulation of certain transcription factors that could 
play a very important role in the ability of the cell to become cancerous [320]. 
The current study 
In a preliminary experiment during purification of the FREBP, HeLa cells 
were grown in suspension in order to get sufficient amount of cells for protein purification. 
Nuclear extracts were prepared from these suspended cells and EMSA's run with 
radiolabeled FRE oligonucleotide. The FREBP activity was decreased in these suspended 
cells as compared to the monolayer cells. The results from these experiments done with HeLa 
cells suggested that the FREBP is an anchorage dependent protein (By Lee Bendickson and 
Christian Paxton, unpublished data). The current study was undertaken to first verify and 
then extend this finding in terms of its application to other fields of study. The focus of this 
study was mainly to identify key signal transduction molecules involved in regulation of the 
FREBP and to outline the pathway that regulates the FREBP in an anchorage dependent 
manner. The FRE is the transcriptional element that regulates the expression of mrp3 gene in 
response to bFGF and this FRE/FRE-like element (sequence with a difference of 1-2bp with 
the FRE) is also present in many mmp genes like stromelysin-1, collagenase type 1, 
gelatinase B. FRE-like sequences from the MMP family members like stromelysin-1 (human 
and rat) and collagenase type 1 (mouse) were capable of binding proteins in nuclear extracts 
from various cell lines and depicted a mobility shift in the band at a position similar to the 
one seen with FRE with FREBP. Also, successful competition binding was observed with the 
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previously mentioned MMP family member sequences for the proteins binding to the FRE as 
well as for proteins binding to the FRE like sequences [313]. It was then hypothesized, 
taking the above data into consideration, that this FRElFRE-like element from the mmp genes 
could be binding to the same protein (s) that binds the FRE from the mrp3 gene [306]. 
Because the FREBP is proposed to be the transcription factor that regulates 
the expression of the FRE-containing mrp3 gene as well as the mmp genes in response to 
bFGF, this study would provide us an in depth insight into the signaling pathway and the key 
molecule that regulates the FREBP and in turn give us information on the pathway that 
regulates expression of the mrp3 and mmp genes. Furthermore, in the long term, this study 
would help establish a bFGF-regulated pathway that could be involved in the regulation of 
several important genes during physiological and pathological conditions that have the 
transcriptional element FRE in their promoters. It would enable us to understand and 
establish the mechanism by which bFGF regulates gene expression during conditions like 
tissue remodeling and cancer. The mmp genes that we propose are regulated by the FREBP in 
response to bFGF are activated during various physiological and pathological processes 
including various tissue remodeling events and several different types of cancer. Hence with 
this study we would have more information on how these genes are being regulated in these 
events. We would also have a better understanding of the mechanism of action adopted by 
bFGF and perhaps of other members of the FGF family of growth factors in regulating the 
mmp genes. 
Integrins themselves, along with molecules from the previously mentioned 
pathways like MEK and FAK, are now established as playing an active role in cancer 
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development as well as being effective targets for cancer therapy [321 ]. Thus, identifying the 
specific molecules that regulate the FREBP in an anchorage dependent manner would be 
very useful in defining the role, if any, that the FREBP plays during tissue remodeling and/or 
cancer. This pathway could be new or one that has been previously described and is already 
well established. 
Once it was determined that the FREBP is an anchorage dependent protein, it was 
pertinent to know whether it plays any role in the cell's ability to become anchorage 
independent. The property of FREBP being anchorage dependent gave us a very important 
clue pertaining to the involvement of the ECM and also the nature of the pathways that could 
be involved in its regulation. This finding was important as certain mmp 's are also regulated 
by interactions with the cell surface like mmp-2, mmp-3, mmp-7 and mmp-9 [191, 322].To 
identify and map out the signal transduction pathway by which the FREBP is regulated, 
pathways that are already known to be regulated by the extracellular matrix like the MAP 
Kinase, FAK and PI-3 Kinase, were identified for investigation. Protein kinases and other 
proteins in these pathways like FAK, Src kinase, PI-3 kinase, Ras and MEK were identi~ ed 
as key molecules that are activated or participate in the signal transduction pathways that are 
regulated directly or indirectly by the ECM. Inhibitors of these molecules were used in 
studies with cell cultures either in a monolayer or in suspension cultures. 
The results from these studies showed that a MEK inhibitor PD 98059 inhibits 
FREBP activity in cells that were adherent to the ECM and thus our interpretation was that 
MEK might be involved in regulating the FREBP activity in monolayer HeLa cells. PD 
98059 binds to inactive MEKl and prevents its phosphorylation and activation by Raf. It 
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does not inhibit all protein kinases but specifically inhibits activation of MEK protein kinase 
by Raf protein kinase. It also has an inhibitory effect on ERKS and cyclo-oxygenases 1 and 2 
at a higher concentration [323] [324]. A key question was whether MEK activity was 
anchorage dependent. This question was tested in two ways; first, the activity of MEK was 
established in suspension cultures of HeLa cells over the same time course as decreasing 
FREBP activity and second, we determined the effect of inhibiting MEK activity over the 
same time course in suspension cultures as the time course established for the declining 
FREBP activity. MEK activity was assessed by Western blot. Antibodies for its direct 
substrate, ERK (totalERK and phosphoERK) were used. Results from this study showed us 
that the activity of MEK decreases more slowly than the FREBP activity in HeLa cells 
placed in suspension cultures and inhibiting MEK in suspension cultures did not have an 
effect on the FREBP activity in suspended cells. Hence based on our studies we propose that 
MEK could be involved in the regulation of FREBP in monolayer cells but not in suspension 
cultures of HeLa cells. 
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MATERIALS AND METHODS 
Promoter Analysis: The FRE sequence was compared with the proximal promoters 
of the MMP family members known to be regulated by bFGF using the following searches: 
BLASTN from Pub Med (Nucleotide-nucleotide blast and search for short nearly exact 
matches). 
Materials: MEK inhibitor PD 98059, Src Kinase inhibitor PP2 and negative control 
PP3, PI-3 Kinase inhibitor LY 294002 and negative control LY 304002, p38 MAP Kinase 
inhibitor SB203580 were purchased from Calbiochem (La Jolla, CA). Antibodies to 
phospho-ERK (PERK) and total-ERK (tERK) (BD Biosciences) were a gift from Dr. Janice 
Buss (Iowa State University, Ames, IA). Secondary antibody horseradish peroxidase- 
conjugated anti-mouse was from Santa Cruz Biotechnology. The ECL Western blot analysis 
detection reagent was from Amersham Biosciences (Buckinghamshire, LJK). The purified 
double stranded AP1 consensus Oligonucleotide (5'-CGCTTGATGAGTCAGCCGGAA-3') 
was purchased from Promega, Corp. (Madison, WI) and the FRE Oligonucleotide (5'- 
CTATATCAGTGAATCTAAAA-3') was purchased from the DNA sequencing and 
synthesis Facility (Iowa State University, Ames, IA). poly (dI-dC): poly (dI-dC) was from 
Pharmacia Biotech, Inc. (Piscataway, NJ). T4 polynucleotide Kinase was from Promega 
Facility at Iowa State University, Ames, IA. 
Cell Culture and Suspension: HeLa cells were grown in Dulbecco-Vogt's modified 
Eagle's medium (DMEG) with addition of 10% bovine calf serum and 10 U/ml each of 
penicillin and streptomycin (GIBCO/BRL, Grand Island, NY). The cells were maintained on 
a incubator supplied with 10% CO2 and 90% air at 37° C. Cells were suspended in 50 ml 
spinner flask on Bell-stir multi-stir magnetic stirrer (Bellco glass Inc., USA) at speed 4 for 
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different time periods of suspension. Cells were detached using 0.25% trypsin/EDTA either 
from monolayer or from suspension and were then collected by spinning at 5000 rpm in 
model HN-S centrifuge and used for preparing nuclear extracts or whole cell extracts. 
Samples were normalized to the amount of protein determined by the Bradford assay using 
Coomassie Plus Protein Assay Reagent (Pierce, Rockford, IL). 
Nuclear Extract: Nuclei were isolated from Hela cells (monolayer, suspension, 
with/without treatment with inhibitors) using 1.2M KCL. The cells were washed with cold 
TBS and resuspended in cold hypotonic buffer (10 mM HEPES, 1.5 mM MgCl2, 10 rr~1VI 
KC1, 0.2 mM PMSF and 0.5 mM DTT). The cells were then transferred to a Dounce 
homogenizer embedded in ice and homogenized using a type B pestle. Cells were centrifuged 
at 3300xg for 5 min (Model 541 S centrifuge). Nuclei were resuspended in low salt buffer (20 
mM HEPES, ZS% Glycerol, 1.5 mM MgCl2, 0.02 M KCI, 0.2 mM EDTA, 0.2 mM PMSF, 
0.5 mM DTT) and high salt buffer (20 mM HEPES, 25% Glycerol, 1.5 mM MgCl2, 1.2 M 
KC1, 0.2 mM EDTA, 0.2 mM PMSF and 0. S mM DTT) and these buffers were added drop 
wise equal to %2 packed nuclear volume each. This mixture was extracted for 30 min in tube 
rotator at 4° C. The extracted nuclei were centrifuged at 16000xg for 5 min (Model 5415 
centrifuge) and the extract collected. It was then dialyzed for 12 h in dialysis buffer (20 mM 
HEPES, 20% Glycerol, 100 mM KC1, 0.2 mM EDTA, 0.2 mM PMSF, and 0.5 naM DTT) 
and stored at —80° until further analysis. The nuclear extracts were analyzed by 
electrophoretic mobility shift assay (EMSA) to asses the FRE-FREBP binding. 
Whole Cell Extract Preparation: HeLa cells grown as described above were taken 
from monolayer or suspension time points and were lysed with 1 X SDS electrophoresis 
sample buffer (61.5 mM Tris, 10.5% Glycerol, 0.0015% Bromophenol Blue, 72 mM SDS) 
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using a tuberculin syringe (the whole cells extract was triturated a few times to break DNA) 
and stored at —80° until further analyzed by performing a Western blot as described below. 
Oligonucleotides and Probes: Double-stranded 32P -labeled oligonucleotides were 
end-labeled using T4 polynucleotide kinase (Promega) in the presence of ['y 32P] ATP (5000 
Ci/mmol; ICN Pharmaceuticals, Inc., Costa Mesa, CA), 0.1 mM EDTA, 10 mM NaCI, 10 
mM MgCl2 and 5 mM DTT. Unincorporated radiolabel was removed using STE SELECT-D, 
G-25 spin columns (Bio-Rad, Hercules, CA). The probes were stored at —20°. 
DNA-Protein Binding Electro phoretic mobility shift assay (EMSA): Nuclear 
extracts from HeLa cells that had been grown as monolayer or put in suspension for specific 
time periods or treated with the above inhibitors or their negative controls. Binding reactions 
(20u1) were prepared containing 300 ug/ml BSA, 55 mM KCI, 0.11 mM EDTA, 2 mM 
MgC12, 0.1 mM PMSF. 0.28 mM DTT, 100 ug/ml poly (dI-dC); poly (dI-dC), 19% glycerol, 
4 mM Tris • Cl, 19 mM HEPES and 16 pgiul P32-FRE or 12 pg/ul P32-AP 1 double-stranded 
DNA probes with equal protein for each individual experiment was loaded on the gels. The 
reaction mixes were incubated at 30°C for 30 min. DNA-protein complexes were separated 
from free probe by electrophoresis on 4% polyacrylamide gel (80:1 acrylamide: 
bisacrylamide) in 2.7 mM EDTA, 380 mM glycine, 2.5% glycerol, 50 rriM Tris•Cl, pH 8.5. 
Gels were run at 100mv (for 2 h, constant voltage, in cold room), dried overnight, exposed to 
PhosphorScreen (Molecular Dynamics, Sunnyvale, CA), analyzed on a PhosphoImager and 
quantitated using ImageQuant software (Amersham Biosciences). 
Western Blot Analysis: Whole cell extracts were collected as described above from 
Hela cells in suspension over different time periods and analyzed by Western blot for 
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phospho-ERK (PERK) and total ERK (tERK). Samples were run on a 15% polyacrylamide-
SDS gel at constant 25 mAmp, 300V/gel for ~50 min at room temperature. The proteins were 
electroblotted to nitrocellulose membranes (Nitrobind; Osmonics, Westborough, MA) using 
Hoefer TE 50 apparatus at constant 400 mAmp, 17 V/gel for 2h. The membrane was stained 
with 0.2% Ponceau S in 3% trichloroacetic acid staining solution at room temperature for ~2 
min to ascertain uniform transfer of proteins to the membrane. After destaining with water, 
the membrane was incubated for lh at room temperature in blocking solution [5% BSA in 
TBS { 1 XTD (13 5.6 mM NaC 1, 5 mM KC 1, 1 mM Na2HP 0 4 and 2 5 mM Tri s), 0.7 uM C aC 12
and 2 uM MgCl2 } + 0.2% Tween 20] . The blocking solution was then decanted and the 
membrane was washed 3 times for S min each with TBST (TBS + 0.2% Tween 20). The 
membrane was soaked in a blocking solution containing our first primary antibody (anti- 
tERK at a dilution of 1/1000) overnight at 4° C on a Rocker at speed 4. The membrane was 
again washed three times for 10 min each with TBST, and soaked in blocking solution 
containing secondary antibody (horseradish peroxidase-conjugated anti-mouse at a dilution 
of 1 / 10,000 from Santa Cruz Biotechnology) for 1 h at room temp on shaker at speed 4. The 
membrane was then washed 3 times for 10 min each with TBST and finally stained with ECL 
substrate (Western blotting Analysis reagents, Amersham International, Buckinghamshire, 
UK) and analyzed by autoradiography. The membrane was then incubated at 37° for lh in 
stripping buffer (62.5 mM Tris, 2% SDS and 100 mM beta-mercaptoethanol) and washed 3 
times with TBS. This stripped membrane was reprobed for our second primary antibody 
(rabbit anti-PERK at a dilution of 1/1000) with the exact procedure described above followed 
again. After we had the pictures from autoradiography of both our antibodies the bands were 
quantified using Kodak Imaging System and results analyzed by Prizm Software. 
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RESULTS AND DISCUSSION 
The FRE sequence is present in certain MMP promoters: A systematic search for the 
FRE sequence was performed in the proximal promoters of different MMP family members 
that are regulated by bFGF using the BLAST med and CLUSTEL programs. Interestingly the 
FRE sequence either in its entirety or with a difference of 2-3 base pairs was discovered 
within the identified sequences of MMP family members from both mouse and human 
species (Fig 1). Transcriptional elements, like the GATA and AP-1 transcription factor, 
similar to those observed in the proximal promoter of mrp3, were also found in the proximal 
promoters of the mmp genes. This result further confirmed the initial studies done in our lab 
on the presence of the FRE in the different MMP family members [313]. Because the FRE 
present in the mrp3 promoters has been shown to regulate the expression of mrp3 in response 
to bFGF, it was further hypothesized that the FRE sequences in the mmp promoters could be 
playing a similar role as a transcriptional element in response to bFGF in these genes. 
Fig. 1 
FRE-FREBP binding specificity: TRE, the response element for the AP-1 transcription 
factor is also present in the promoter of the mrp3 gene along with the FRE [225]. We 
conducted further experiments to confirm the specificity of the FRE-FREBP binding and to 
exclude AP-1 as being part of the FRE-FREBP complex. Competition assays were performed 
by EMSA using nuclear extracts from HeLa cells (monolayer and suspension cultures) with 
labeled probes and unlabeled oligonucleotides containing FRE and AP-1 sequences. The AP- 
1 complex migrated more slowly through the gel than the FRE-FREBP complex. Excess 
46 
unlabeled FRE oligonucleotide competed successfully for the FRE-FREBP band and not 
with the AP-1 band. Excess unlabelled AP-1 oligonucleotide did not compete for FRE- 
FREBP binding but competed successfully for AP-1 binding (Fig 2 A). The data was further 
confirmed using quantitative analysis and a significant reduction (** = p < 0.01) was 
observed in the samples for FRE probe and AP-1 probe containing cold FRE 
oligonucleotides and AP-1 oligonucleotides for competition. The FRE-FREBP complex 
binding was competed successfully by the cold FRE oligonucleotide (Lane 3 and 4) and not 
by the cold AP-1 oligonucleotide (Lane 5 and 6). The AP-1-nuclear protein complex binding 
was similarly competed for successfully by cold AP-1 oligonucleotides (Lane 9 and 10) and 
not by the cold FRE oligonucleotides (Lane 11 and 12) (Fig. 2B). Together these results 
showed that FRE-FREBP binding is specific for the FRE sequence. 
Fig. 2 
FREBP activity is anchorage dependent: To confirm the observation that the FREBP 
activity is anchorage dependent and to chart out its time course, HeLa cells were suspended 
for different time periods over the course of 24 h, nuclear extracts were prepared and EMSA 
analysis was performed to analyze FRE-FREBP activity. Our results effectively demonstrate 
that FREBP is an anchorage dependent protein. EMSA analysis showed that FREBP activity 
decreases in atime-dependent manner until no detectable activity was observed at 24h post 
suspension (Fig 3A). Densitometric analysis using Itnagequant was done in order to quantify 
the FREBP activity changes over the period of cell suspension analysis (Fig 3B). 
Furthermore we conducted short time course studies within a period of one hour to determine 
at what time point the loss of activity initiated. The data obtained showed that the activity 
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begins to decline within the first hour and continues until about 10 h (Fig 3C). Taken 
together these results suggested that the FREBP is regulated in an anchorage dependent 
manner. Based on published literature and the knowledge of current work in the lab we 
proposed the involvement of one or more of three major pathways; the MAP kinase cascade, 
FAK pathway and PI-3 Kinase pathway in the regulation of FREBP activity. 
Fig. 3 
Activity of the transcription factor (AP-1) is not anchorage dependent: AP1, an 
established transcription factor, was used to gauge the specificity of the effect of anchorage 
on the regulation of transcriptional activity [315]. The following experiments were done to 
determine whether AP-1 also followed a similar anchorage dependent response as the 
FREBP in HeLa cells after the cells were suspended. The activity of AP-1 was monitored in 
the same samples in which the FREBP activity was monitored (Fig. 3). EMSA analysis 
showed no reduction in the AP-1 activity in HeLa cell suspension studies even up to 12 h 
after initiation of suspension (Fig 4A) and these results, which were further quantified by 
analyzing PhosphoImager scans (Fig 4B), indicated no significant changes in activity of AP- 
1 with increase in time of suspension. Our results suggested that FREBP is uniquely an 
anchorage dependent transcription factor. A THE (AP-1-binding site) is present in the 
promoter of mrp3 gene and it was investigated for its role in regulating mrp3 in response to 
bFGF by the following experiments. Serum and protein kinase C (PKC) can activate Jun and 
Fos transcription factors that are regulated through the TRE. It was shown that down 
regulation of serum and PKC did not affect the activation of mrp3 in response to bFGF. 
Hence it was postulated that the THE is not taking a part in the regulation of mrp3 in 
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response to bFGF [225]. Our results further show that AP-1 activity unlike the FREBP 
activity is not anchorage—dependent in HeLa cells. 
Fig. 4 
MEK involvement in the regulation of FREBP activity: Signal transduction molecules 
that were known to participate in ECM regulated pathways were selected for our study. 
These were MEK, Src Kinase, PI-3 Kinase and Ras. Inhibitors were used for each of these 
molecules when the cells were grown in monolayer cultures. These studies were undertaken 
to assess the affect of each inhibitor on the FREBP activity and to determine if any of these 
molecule could be involved in regulating the FREBP. Nuclear extracts were prepared as 
described previously and DNA and DNA-protein complexes separated by running EMSA 
gels. The FREBP activity was analyzed by exposing the gels to PhosphoImager and bands 
quantified by using ImageQuant software. The well-characterized MEK inhibitor, PD 98059, 
attenuated FREBP activity in monolayer HeLa cells (Fig 5). This suggested that MEK, an 
important molecule of the MAP kinase pathway could be involved in regulating the FREBP 
aCtlVlty. 
Fig. 5 
PI-3 Kinase, Src Kinase and Ras are not Involved in regulating the FREBP activity: In 
this set of experiments we investigated if the other selected molecules played any role in the 
development of FREBP activity. The inhibitors and doses that were used are as follows; 
LY294002 (PI3K inhibitor-50 µM), PP2 (Src kinase inhibitor-30µM) and Ftase (Ras 
inhibitor-20 µM). All doses were selected based on an extensive search of current and past 
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relevant literature. The inhibitors used had no significant effect on the FREBP activity in 
monolayer cells, which indicated that these molecules possibly do not regulate FREBP 
activity while the cells are in monolayer and still attached to the ECM. Further experiments 
with these inhibitors with cells in suspension were not undertaken. 
These results narrowed down our scope of identifying the signal transduction pathway 
involved in regulating the FREBP. Because MEK is downstream of Ras in the MAP kinase 
pathway cascade certain questions arose from these experiments that remain unanswered at 
this point. In agreement of our earlier finding that inhibiting MEK decreases the FREBP 
activity. Inhibiting Ras should, via the inhibition of the MAP kinase cascade inhibit MEK 
which in turn should inhibit the FREBP activity. We did not see this decrease in FREBP 
activity is response to Ras inhibition. The possible explanation for this result could be that 
either MEK is being activated independent of Ras in our system as has been shown in certain 
other systems [ 17] or the time period of incubation with Ras inhibitor in our study was too 
short for the inhibitor to have its effects. These results need to be further confirmed by 
repeating these experiments. Even though PD 98059 is a very potent and specific inhibitor of 
MEK1, it is also capable of inhibiting ERKS by binding to inactive MEKS and also has a 
inhibitory effect on cyclo-oxygenise 1 and 2. Hence the results from studies using PD 98059 
to inhibit MEK have to be confirmed by other possible experiments like using a dominant 
negative MEK and observing the effects on the FREBP activity. (Fig. 6). 
Fig. 6 
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MEK activity decreases more slowly than FREBP activity after cells are placed in 
suspension: On the basis of the previous results (Fig. 5) it appeared that MEK could play an 
important role in the regulation of the FREBP. To further extend this hypothesis we looked at 
the activity of MEK once the cells are put in suspension cultures without any inhibitor over 
the same time course that we already had established for the decrease in FREBP activity. 
These experiments would give us information regarding the status of MEK activity and by 
comparing it to the FREBP activity over the same time course we can compare the rate of 
decline of FREBP activity to MEK activity. The direct downstream substrate of MEK is 
ERK1/2 and hence we looked at the ability of MEK to phosphorylate ERK as an indicative of 
the change in MEK activity after the induction of cell suspension. By performing Western 
blots we monitored the changes in total ERK (tERK) and phosphoERK (PERK) during the 
same time period that the FREBP activity decreases by performing Western blots. The results 
were quantified by densitometric analysis (Fig. 7B) and it was confirmed after normalizing 
the values for pERK to tERK that the proportion of ERK that is phosphorylated decreases 
more slowly than the activity of the FREBP. The r 2 value of 0.69 indicates a poor fit and the 
p value of <0.0001 show significant decrease in MEK activity. But since we are looking at 
the comparison of MEK activity with FREBP activity, this suggested that MEK activity 
decreases more slowly than FREBP activity after the cells are suspended (Fig 7A). These 
results suggest that it is unlikely that MEK is responsible for the decrease in FREBP activity 
in suspension cultures. This needed further clarification and for that we need to know what 
happened to FREBP activity in suspended cells when the activity of MEK is inhibited. 
Fig. 7 
~~ 
Inhibiting 1V.~EK does not decrease FREBP activity in suspension cultures. Inhibiting 
I~IEK in monolayer has a dose dependent inhibitory erect on the FREBP activity but the 
decrease in activity of ~IEK daes not correspond to the decreasing FREBP activity in 
suspension cultures. I tested the ability of a l~IEK inhibitor to decrease FREBP activity in 
suspended cells. HeLa cells were grown in monolayer cultures and suspended and treated 
with PD g8Q5~! at the times identified. 1VIy results show that there is no effect of inhibiting 
~~K on FREBP activity in suspension cultures (Fig 8a and 8B}. These f riding taken 
together with our earlier findings indicate that although the ~~IEK molecule may be involved 
in regulating the FREBP in monolayer HeLa cells, it does nat regulate the FREBP activity 
directly in suspension cultures. 
Fig. 8 
comparison of FII~BP and AP-1 activity Decay. The half-life of a molecule is the average 
time required far the activity of a substance (proteins, radionucleotides, en2ymes etc} to 
reduce to half of the amount that it started with originally. The calculation of half-life of 
proteins can give us valuable information regarding its activity status. The FREBP activity 
decays much faster compared to the MEK activity in suspended HeLa cells over the same 
time period. ~A~) FREBP and hZEK activity over ~24h. (B) FREBP and l~~EK activity aver 
~8h. The half-life of MEK was calculated to be 18h and the half-life of the FREBP activity 
was calculated to be 2.8h. 
Fig.. 9 
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Effect of p38MAP kinase pathway inhibitor: SB 203 5 80. Results from preliminary 
experiments show that the inhibiting the p3 8 MAP kinase pathway has a 40% reduction in 
the FREBP activity in monolayer HeLa cells. Experiments were not enough to do statistical 
analysis. Further studies have to be conducted to know the significance of these results (Fig. 
10). 
Fig, 10 
Summary. The molecules targeted from the MAP kinase pathway, PI-3 kinase pathway and 
FAK pathway are illustrated along with the inhibitors used for each one of above mentioned 
molecules beside them. 
Fig. 11 
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CONCLUSIONS AND FUTURE DIRECTIONS 
The mrp/plf's and the mmp's are classified as delayed response genes that are 
activated in response to growth factors. Both families of genes encode secreted proteins that 
are involved in the biological processes of cell growth and angiogenesis [325]. Interestingly 
both mrp/plf's and mmp's are also expressed in the physiological as well as pathological 
events of tissue remodeling like wound healing and cancer. There are many similarities 
between the processes of wound healing and cancer like cell proliferation, cell migration and 
invasion, angiogenesis, degradation of basement membrane, activation of similar pathways, 
increased expression of growth factors, growth factor receptors, angiogenic factors along 
with increased expression of similar genes [326] [327] [146]. Recently a model to predict 
cancer has been proposed based on the expression of genes during a fibroblast cellular 
response to serum in cell culture [328]. Fibroblasts from different sites in the body shared a 
common gene expression pattern, which was called a genetic signature. This genetic 
signature was always found in certain cancers like prostate and liver-cell carcinomas and 
variably in others like breast, lung and gastric carcinomas. Patients having tumors containing 
the serum-activated wound-like signature had a worse prognosis compared to ones not 
having this signature [328]. The timing of expression of mrp3 and mmp's are similar in 
during wound healing and cancer. Certain members of both mrp/plf (mrp3) and the mmp 
gene (stromelysin-1, collagenase type 1, gelatinase B) family are regulated by the bFGF. The 
mmp-9 gene is expressed in the outer root sheath hair follicle cells in response to growth 
factors [329] and mrp3 is expressed during wound healing in adults. Furthermore, MRP3 
protein expression is found in the suprabasal keratinocytes at the wound healing sites and in 
the outer root sheath of the hair follicle during the hair growth (late anagen phase) [234]. The 
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FRE transcriptional element present in the proximal promoter of the mrp3 gene was also 
found in many of the bFGF regulated promoter sequences in genes of the mmp family 
(stromelysin-1, collagenase type 1, gelatinase B) as well as those belonging to other protease 
families (cathepsinL, cathepsin B, tissue plasminogen activator). Interestingly, members 
from other protease families (elastase, metalloelastase, trypsin, and chymotrypsin) not 
regulated by bFGF did not contain the FRE or a related sequence [313]. This literature 
analysis closely mirrored our hypothesis of the FRE being involved in the bFGF induced 
physiological cellular processes. The involvement of similar pathways have been proposed 
like the mitogen activated protein kinase (MAPK) pathway in the regulation of MMP family 
members like MMP-1 [195] and mrp/plfs [330]. Owing to the co-incidental expression and 
the similarity of their encoding proteins involved in cellular processes, it is suggested that 
similar transcriptional elements) might be involved in the regulation of the mrp/plf's and the 
mmp's. 
The FRE binds to one or more nuclear factors derived from different cell lines 
and from tissues like the placenta (day 11) and fetus. The FRE element linked in three 
tandem repeats upstream of the minimal thymidine kinase CAT reporter gene was shown to 
be bFGF-responsive, hence it was proposed that the protein binding to this FRE is a bFGF 
activated protein. This nuclear factor that binds the FRE was further characterized and 
termed as the fibroblast growth factor response element binding protein (FREBP) with an 
approximate MW of 32-37 kDa. It was hypothesized that this is a transcription factor 
involved in regulating mrp3 gene expression in response to bFGF [313]. Furthermore, 
FREBP activity was found in cells across several species including 3T3 cells from mouse; 
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CHO cells from hamster and Hela cells from humans. FRE-like sequences from different 
MMP family members like stromelysin-1 (human and rat), and collagenase (mouse) were 
capable of binding proteins in the nuclear extracts of the aforementioned cell lines bearing 
remarkable similarity to the established band mobility of FRE. In addition, successful 
competition binding was observed from the previously mentioned MMP family member 
sequences for the proteins binding to the FRE as well as for proteins binding to the FRE like 
sequences [313]. Taken together this data yielded the hypothesis that the same proteins) 
could be binding to the FRE-like elements from the matrix metalloproteinase genes as binds 
to the FRE from the mrp3 gene. 
These findings together led in the direction of establishing the FREBP as a 
new transcription factor involved in the regulation of mrp3 and certain mmp 's (FRE-
containing bFGF regulated genes) in tissue remodeling processes and cancer. The present 
study was done in order to provide further insight into the functional and regulatory aspects 
of FREBP. With these and other studies [308] we demonstrated that the FREBP binding is 
very specific for the FRE and that AP- l , which is present in the proximal promoter of the 
mrp3, was not a part of this complex. The results from EMSA's done with nuclear extracts 
from Hela cells showed that AP-1-protein complex migrated more slowly than the FRE-
FREBP through the acrylamide gel indicating that the two elements, the FRE and TRE, 
formed different protein complexes. Furthermore, excess unlabeled FRE oligonucleotide 
competed successfully for the FRE-FREBP complex but not for the AP-1 complex. In 
addition, excess unlabelled AP-1 oligonucleotide did not compete for the FRE-FREBP 
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complex but competed successfully for the AP-1 complex thus proving effectively that FRE-
FREBP binding was independent of AP-1 activity. 
It was then demonstrated that the FREBP was an anchorage dependent 
protein. Time course studies done with HeLa cells over a period of 0-24h after they were 
placed in suspension showed that the FREBP activity goes down gradually reaching its 
lowest levels by ~12h (Fig. 3B). This observation suggested that probably the FREBP 
activity was being regulated by an ECM dependent pathway. This property of anchorage 
dependence is increasingly becoming the focus of studies involving biological events like 
tissue remodeling, as the cells involved in these events become anchorage independent and 
acquire the ability to move from their original position to different areas. The exact 
mechanism by which the cells acquire this ability is still unclear but it is proposed to be one 
of the major factor regulating cancer cell pathophysiology [331 ]. 
Next our main focus was to identify the pathways and/or molecules that could 
be involved in regulating the FREBP activity in an anchorage dependent manner in these 
cells. This data would help provide a better understanding of the mechanism adopted by 
cancer cells in their ability to become anchorage independent. These results would also help 
in making the connection of FREBP activity to the mmp's since it has already been 
demonstrated that certain mmp's (mmp-2,3,7 and 9) are also regulated by interactions with 
the cell surface [322] [191). In the subsequent experiments we showed, through timed 
suspension studies, that the time course of decline in FREBP activity starts within the first 
hour and decreases for the first 8-10 h. It was also demonstrated that the phenomenon of 
anchorage dependence was exclusive for FREBP activity and AP-1 activity did not change 
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similarly. EMSA analysis depicted no reduction in the AP-1 activity in HeLa cell suspension 
studies even up to 12 h after initiation of suspension (Fig 4A) and these results were further 
quantified using Densitometric analysis (Fig 4B) indicated no significant changes in activity 
with increase in time of suspension up to ~24h. Studies have shown that the AP-1 response 
element THE is present in the promoter of mrp3 gene [225] but it was shown that AP-1 is not 
part of the regulation of mrp3 by bFGF as both serum and PKC can activate Jun and Fos 
transcription factors but down regulation of serum or PKC did not affect the bFGF regulation 
of mrp3 [313J. Our finding are in corroboration with these earlier studies done describing the 
role of AP-1 in regulation of mrp3 in response to bFGF. Our studies further strengthened the 
belief that the FREBP functions as a separate transcription factor by a mechanism distinct 
from AP-1 since the latter was not regulated in an anchorage dependent manner while the 
former was in the same experimental setup. The ramifications of decreasing FREBP activity 
in response to loss of anchorage could vary from the suppression of genes that it is directly 
activating and in increasing activity of genes it might be helping to suppress under normal 
conditions. The activation of genes that it could be suppressing further might lead to the 
activation of new genes. 
These studies also helped in narrowing down the kind of pathway that could 
be involved in the FREBP regulation because it became evident that an extracellular matrix 
(ECM) regulated pathway was involved in regulating the FREBP in an anchorage dependent 
manner. Based on this observation and extensive literature review, the MAP kinase, 
phosphoionositol-3 (PI-3) kinase and the focal adhesion kinase (FAK) pathways were 
narrowed down as candidate for studies. These pathways are activated in response to growth 
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factors as well as in response to ECM via cell surface receptors like integrins. These 
pathways can each act on different transcription factors that in turn regulate myriad cellular 
processes. Recent investigations have shown that the MAP kinase pathway can regulate 
transcription factors like Elk-1, MEF2A, GATA-1, Jung and Rskl [332]. Based on further 
analysis we chose certain specific molecules from these pathways like MEK kinase, Src 
kinase, PI-3 kinase and Ras to be studied as possible modulators of FREBP activity in the 
cellular model of anchorage dependence. These molecules, like constitutively active MEKI, 
have already been well established for playing a role in regulating several genes, like mmp-2, 
involved in tissue remodeling and cancer in response to ECM adhesion [198]. 
Our studies in monolayer cultures indicated that among the various inhibitors 
we investigated, a MEK inhibitor PD 98059 decreases FREBP activity significantly in 
monolayer HeLa cells (Fig. 5). MEK, a member of the MAP kinase pathway, is considered 
very important because of its presence and high activity demonstrated in several cancerous 
lesions and it has been postulated as an important player in the cell's decision to become 
anchorage dependent [59] .The MEK inhibitor PD 98059, has been studied extensively and 
is at present part of a clinical trial to be developed as a therapeutic measure against 
development of cancerous pathology [333]. PD 98059 inhibits the MAP kinase pathway in 
vitro and in vivo by the specific interaction with its target kinase and not by disruption of the 
ATP metabolic mechanisms in the cell [334]. The activation of plasminogen activator 
inhibitor-1 gene is induced by ECM attachment via two transcriptional elements present in its 
promoter: serum response element (SRE) and hypoxia response element (HRE). It was 
shown that the binding ability of these transcriptional elements to their nucleoproteins was 
cell adhesion dependent and also MEK dependent [335]. Although we had already 
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established that the FREBP activity is anchorage dependent, we further demonstrated its 
functional connection with MEK. 
We further extended our hypothesis to include that MEK could be involved in 
regulating the FREBP activity not only in monolayer cells but also by regulating FREBP in 
an anchorage dependent manner. In order to answer this question we determined the effect on 
MEK activity of placing HeLa cells in suspension over a similar time course to that used to 
measure the rate of decline of FREBP activity. Furthermore, studies were also done to 
investigate the effect on FREBP activity in suspended HeLa cells when MEK is inhibited. 
The activity of MEK in suspension cultures was examined over a time course similar to that 
where we had observed a decreasing FREBP activity. Antibodies for the direct substrates of 
MEK, tERK and pERK were used. Results were quantified by normalizing the pERK values 
to tERK values. Our data indicated that the pERK activity did not decrease significantly over 
the period of time that we had observed a significant drop in FREBP activity (Fig. 7). Based 
on these results it was established that the process of FREBP activation was independent of 
MEK activity in the case of suspended HeLa cells. In the next study we tested if inhibiting 
MEK in suspension cultures decreased FREBP activity. MEK inhibitor PD98059 was used to 
inhibit MEK in HeLa cells that had been placed in suspension for 30 min and 12 h and the 
effect on FREBP activity was analyzed. The results showed that inhibiting MEK does not 
inhibit FREBP activity in suspension cultures (Fig. 8) further establishing the hypothesis that 
in suspended HeLa cells the FREBP activity is not being directly regulated by MEK. 
Analysis of the half-life of the decrease in activity of the FREBP and MEK 
showed that the FREBP activity in suspended HeLa cells decayed at a much faster rate than 
the MEK activity (Fig. 9). I believe there can be two possible causes for these results to be 
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observed. First, that even though MEK may regulate FREBP in monolayer HeLa cells, it is 
not directly involved in the regulation of FREBP in suspension cultures. This explanation can 
be clarified by investigation of the indirect role of MEK in suspension cultures and 
involvement of other co-regulators. Secondly, the results of studies done by others on the 
factors affecting the nucleocytoplasmic distribution of MAP kinase pathway suggest an
explanation for our results. It has been demonstrated that integrin mediated cell adhesion 
differentially regulates the nucleocytoplasmic distribution and translocation of ERK and the 
subsequent phosphorylation of its nuclear substrate Elk-1 at serine 383. The ability of 
activated ERK to localize to the nucleus and to phosphorylate its nuclear substrates was 
markedly decreased when the cells were in suspension versus attached and ERK activity was 
dependent on an intact actin cytoskeleton [55]. Interestingly, it was further established that 
this effect on ERK was restricted to the ERK-MAPK cascade and does not extend to the JNK 
or p38-MAPK kinase pathway. Anchorage-independent activation of the JNK and p38- 
MAPK pathway in NIH 3T3 cells showed that the ability of JNK to localize to the nucleus 
and phosphorylate substrates (c-Jun and Elk-1) mirrored the activation characteristics of p38 
and was the same in suspended and adherent cells [62]. Based on these studies it is possible 
that once in suspension the ability of ERK to phosphorylate the FREBP is markedly 
attenuated in comparison to the cells that are in monolayer cultures. Further clarification can 
be afforded by determining the effect of cell suspension on ERK activity in nuclear fractions 
from HeLa cell extracts. Using the same nuclear extracts used for the FREBP study will give 
us data to compare the FREBP and ERK activity in the nucleus of HeLa cells in suspension. 
Preliminary studies have been also been done to determine effects of inhibiting p38 MAP 
kinase on the FREBP activity. Attenuating the p38MAP kinase pathway using a specific 
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inhibitor SB 203580 in monolayer HeLa cells did not have any affect on the FREBP activity 
(Fig.10). 
In summary these results showed that inhibiting MEK activity decreases the 
FREBP activity in monolayer cells yet the MEK inhibitor PD 98059 has no effect on FREBP 
activity in suspension systems. Hence MEK could be playing an important role in the 
regulation of FREBP in monolayer cells but it is not directly involved in the FREBP 
regulation in suspension cultures. We need to further elucidate the role of MEK in FREBP 
regulation, whether it is a direct relation and if not what are the other molecules participating 
in this phenomenon. 
Future work investigating the mechanism that regulates the FREBP in an 
anchorage dependent manner and other studies to further investigate the effect on FREBP 
activity of MEK inhibition in monolayer HeLa cells need to be done. Simultaneously, further 
experiments need to be performed in order to establish the connection of FREBP to the mmp 
genes and determine its role if any in the regulation of the FRE containing mmp 's. These 
studies would be very useful as not only will they establish whether the FREBP regulates 
expression of the FRE-containing genes in response to bFGF but they will also give us more 
understanding to the type of molecules participating in the cell's ability to become anchorage 
dependent. 
In this regard the following approaches and experiments are suggested. Studies mutants 
like dominant negatives of MEK or constitutively active MEK can be done to further confirm 
whether MEK is involved in regulating the FREBP activity. Those studies should be 
compared with the inhibitor studies and the data analyzed together. In order to establish if 
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ERK could be involved in the phosphorylation of FREBP, the activity status of ERK in the 
nuclear extracts needs to be established. For these experiments antibody against a known 
substrate of ERK, ELK-1 can be used in HeLa cell nuclear extracts and compared with the 
inhibitor studies. Using an ERK inhibitor in monolayer HeLa cells can further confirm the 
role of ERK on FREBP activity in our system. Establishing the time course of the expression 
of mmp 's containing the FRE by doing RT-PCR in HeLa cells over the same time course as 
decreasing FREBP will give us a very useful tool in assessing whether there is any decline in 
the expression of the mmp 's and how does it correspond to the decline in FREBP activity. 
The preliminary studies done with the p3 8 MAP kinase inhibitor show a 40% decline in the 
FREBP activity in monolayer HeLa cells. These studies need to be extended more and results 
obtained from enough experiments in order to establish any significance. It is of prime 
importance before starting any other investigation to get the purified FREBP. Then its 
sequence can be compared to the databases for any similarities with the already established 
transcription factors and based on those results future course decided. Then we need to have 
the cloned cDNA encoding FREBP and this will open a door to many possibilities. This will 
enable us to characterize the structure of FREBP and its function. Anti-FREBP antibody 
could be prepared and by doing Northern blots the presence of its mRNA in tissues and cells 
can be mapped out. It can be determined if the protein regulates the genes containing the 
FR.E in their promoters like the mrp3 and mmp's. Characterization of the DNA binding 
domain of the FREBP to finding its co-regulators and also if it functions in conjunction with 
other transcription factor by forming heterodimers with them can be achieved. Mutagenesis 
studies with FREBP showing the effects if any on the mrp3 and mmp gene expression can be 
planned in promoter-reporter experiments. Preparation of dominant negatives of MEK and 
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FREBP and performing microarray experiments would identify the kind of genes being 
expressed and whether there is an association with the mmp 's. 
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FIGURE S 
Figure 1. Promoter Analysis. The FRE sequence from the proximal promoter of mrp3 was 
compared with different mmp promoters, known to be regulated by bFGF, using the search 
engine BLASTN and CLUSTAL from Pub Med. 
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Figure 2. Co`npetition studies for FRE and AP-1. (A) FRE-FREBP binding specificity was 
analyzed by competition using the EMSA assay. The FRE and AP-1 oligonucleotide 
sequences were used as probes (radiolabeled) and as competitors (unlabeled and 100 times 
the probe concentrations). The positions are labeled of complexes formed by the FRE (with 
FREBP) and AP-1 (with AP1 proteins) with the same nuclear extracts from HeLa cells. 
METHODS: nuclear extracts from HeLa cells were prepared as described in material and 
methods and incubated with radiolabeled oligonucleotides of either FRE or AP-1. Some of 
the incubation mixtures contained 100-fold excess of unlabeled oligonucleotide competitor as 
indicated on the figure. The samples were resolved by gel electrophoresis and the 
radioactivity present in each band was detected by a Phosphoimager and analyzed by 
Imagequant software. (B) A quantitative summary of data representing band shift analysis of 
the complexes depicted in Figure 2A. 
STATISTICAL ANALYSIS: Data represents N=2-4 Mean ± SEM and ** = p < 0.05 
represents significant differences between control and treated groups based on one-way 
ANOVA using Bonferroni's Multiple Comparison Test. 
Fig 2 
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Figure 3. FREBP activity is anchorage dependent. (A) It was established through a series of 
experiments in which the FREBP activity was measured after the cells were suspended that 
the FREBP is an anchorage dependent protein. (B) A time course describing the decline in its 
activity was established from 0-24h. METHODS: HeLa cells were grown in monolayer 
cultures and put in suspension (using spinner flasks) over the time points identified on the 
gel. Nuclear extracts were prepared as described in material and methods and incubated with 
radiolabeled FRE oligonucleotide. The DNA and DNA-protein complexes were separated by 
EMSA (Electro phoretic mobility shift assay). The amount of shifted FRE in each sample 
was analyzed by exposing gels to Phosphoimager and quantified by Imagequant Software. 
Equal amounts of nuclear protein were loaded in each well. 
Fig 3 
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Figure 4. AP-1 is not anchorage dependent. A time course for the AP-1 activity after 
placing HeLa cells in suspension was established that shows that AP-1 unlike FREBP is not 
an anchorage dependent protein in HeLa cell extracts. (A) Depicts a representative EMSA 
showing no significant changes in AP-1 activity in HeLa cell extracts over a period of 12h 
post suspension and (B) depicts a quantitative summary analysis of the AP-1 complex 
density measurements showing no significant changes in AP-1 activity over the entire period 
of measurement from 0-24h. METHODS: Nuclear extracts analyzed previously for FREBP 
were incubated with radiolabeled AP-1 oligonucleotide. The DNA and DNA-protein 
complexes were separated by EMSA. The mobility shifts were analyzed by exposing the gels 
to Phosphoimager and quantifying by Imagequant Software. ANOVA analysis did not reveal 
any significant differences in APl activity up ti1124h. 
STATISTICAL ANALYSIS: Data represents N=1-4 Mean ± SEM. One way ANOVA 
analysis using Dunnett's Multiple Comparison Test showed no significant differences 
between analyzed groups as depicted below. 
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Figure 5. Inhibiting MEK inhibits the FREBP in monolayer HeLa cell cultures. 
METHODS: HeLa cells were grown in monolayer (in DMEG, 10% CS and 10 u/ml P/S) and 
treated with for 2h and 4h with PD98059 in DMSO for the previously identified 
concentrations or with DMSO alone. Nuclear extracts were prepared and incubated with 
radiolabeled FRE oligonucleotide. The DNA-protein complexes were analyzed by EMSA. 
The DNA-protein complexes were quantitatively analyzed by exposing the gels to 
Phosphoimager and quantifying by Imagequant Software. The PD 98059 decreased the 
FREBP activity as compared to the activity levels seen in the control DMSO treated cells. 
STATISTICAL ANALYSIS: Data represents N=4 Mean ± SEM. One way ANOVA analysis 
using Bonferroni's Multiple Comparison Test yielded signi~ cant differences between and 
DMSO and treatment groups * * * = p < 0.001. 
Fig 5 
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Figure 6. Inhibiting PI-3 kinase, Src kinase and Ras does not change the FREBP activity. 
Inhibitors for PI-3 kinase (LY 294002), Src Kinase (PP2) and Ras (FTase) did not have any 
effect on the FREBP binding as seen in HeLa cell monolayer studies. METHODS: HeLa 
cells were grown in monolayer (in DMEG, 10% CS and 10 u/ml P/S) and treated with LY 
294002 (50 uM), PP2 (30 uM) and FTase inhibitor (20 uM) for 2h. Nuclear extracts were 
prepared as described in material and methods and incubated with radiolabeled FRE 
oligonucleotide. The DNA and DNA-protein complexes were separated by electrophoresis 
and the mobility shifts analyzed by exposing the gel to a PhosphoImager and quantifying by 
Imagequant Software. Although the inhibitor treatments did show some reduction in values, 
it was not statistically significant. The negative controls for LY294002 (LY30) and PP2 
(PP3) showed no difference from the inhibitors. 
STATISTICAL ANALYSIS: Data represents N=4 Mean ± SEM. One way ANOVA analysis 
using Bonferroni's Multiple Comparison Test yielded no significant differences between and 
DMSO and treatment groups. 
Fig 6 
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Figure 7. MEK activity decreases more slowly than the FREBP activity when cells are 
placed ire suspension cultures. (A) Gel pictures depict the time course of MEK activity in 
suspended HeLa cells for the time points identified. Antibodies for ERK, the direct substrate 
of MEK, were used (tERK: total ERK and pERK: Phospho ERK) and each sample 
normalized for tERK. (B) Summary of the results for MEK activity. METHODS: HeLa cells 
were grown in monolayer and put in suspension (using spinner flasks) for the time points 
identified. Whole cell extracts were prepared as described in Materials and Methods and the 
samples were analyzed by Western Blots. Antibody for tERK and pERK were used on the 
same membrane. The membrane was first stained with Ponceau S, then blotted for tERK, 
stripped and then blotted for pERK respectively. ECL detection kit was used for detecting 
proteins and the bands were quantified by using Kodak Imaging system. 
STATISTICAL ANALYSIS: Data represents N=4 Mean ± SEM. One way ANOVA yielded 
no significant differences between analyzed groups at p >0.05. 
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Figure 8. FREBP activity is not affected by inhibiting MEK in suspension. (A) Summary of 
the results for the FREBP activity after treatment with PD 98059 for 30 min or 12h. 
METHODS: HeLa cells were grown in monolayer and put in suspension (using spinner 
flasks and treated with 25 uM PD 98059 for the time points identified). Nuclear extracts were 
prepared as described in Materials and Methods. Samples were incubated with radiolabeled 
FRE oligonucleotide and DNA and DNA-protein complexes were separated by EMSA gel. 
The DNA-protein complexes were analyzed by exposing to Phosphoimager and quantified 
by Imagequant Software. Paired t-test analysis showed no significant differences between 
DMSO and PD+DMSO samples at 30 min and 12 h. 
STATISTICAL ANALYSIS: Data represents N=4 Mean ± SEM. One way ANOVA analysis 
and paired t-test yielded no significant differences between analyzed groups at p >0.05. 
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Figure 9. Comparative analysis of decay in FREBP and MEK activity. The FREBP decay is 
much faster compared to the MEK activity decay in suspended HeLa cells over the same 
time course. (A) Comparison of FREBP and MEK activity over ~24h. (B) Comparison of 
FREBP and MEK activity over ---8h. The Half-life of MEK is 18h and FREBP is 2.8h. 
STATISTICAL ANALYSIS: Data represents N=5 Mean ± SEM. Half life was calculated 
using non-linear regression curve fitting using Graph Pad PRISM® Software. 
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Figure 10. Effect of inhibiting p38 MAP kinase pathway on the FREBP activity. 
METHODS: HeLa cells were grown in monolayer (in DMEG, 10% CS and 10 u/ml P/S) and 
treated with for 2h with SB203580 in DMSO for the previously identified concentrations or 
with DMSO alone. Nuclear extracts were prepared and incubated with radiolabeled FRE 
oligonucleotide. The DNA-protein complexes were analyzed by EMSA. The SB 203580 
decreased the FREBP activity by 40% as compared to the activity levels seen in the control 
DMSO treated cells. The significance of these results could not be determined as there were 
not enough experiments for statistical analysis. 
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Figure 11. Summary chart. The molecules targeted from the MAP kinase pathway, PI-3 
kinase pathway and FAK pathway are illustrated along with the inhibitors used for each one 
ofabove-mentioned molecules beside them. 
Fig 11 
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